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Introduction 
 
The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates 
data on CDC-funded HIV testing, linkage to HIV medical care, and HIV prevention services.  
Test-level data are reported by CDC grantees through the National HIV Prevention Program 
Monitoring and Evaluation (NHM&E) system. These data are used to describe the demographics 
of persons tested and other programmatic activities that are funded by CDC, including linkage 
to HIV medical care, partner services, and HIV prevention services.  The report on CDC-Funded 
HIV Testing: United States, Puerto Rico & U.S. Virgin Islands, 2013 (hereafter: 2013 annual 
HIV testing report) summarizes the test event-level NHM&E data for CDC-funded testing 
events in the United States and dependent areas (Puerto Rico and U.S. Virgin Islands).  
 
This report includes HIV testing data from 61 CDC-funded health department jurisdictions and 
151 directly funded community-based organizations (CBOs).  It would not be possible without 
the collaboration, dedication and hard work of grantees from all state, territorial and local 
health departments and CBOs.  The Testing Monitoring and Evaluation Team (TMET) in the 
Division of HIV/AIDS Prevention’s (DHAP) Program Evaluation Branch (PEB) reviewed the 
completeness and quality of the HIV testing data submitted by grantees to determine data for 
inclusion in this report.  CDC staff worked with all health department grantees and project 
officers to ensure that their jurisdiction’s HIV testing data were as complete as possible and of 
high quality.  Test-level data are reported from all 61 health department jurisdictions.1   
 
NHM&E HIV testing data are used in conjunction with other information (e.g., progress reports, 
surveillance data, and census data) by HIV program managers and policy makers, HIV testing 
service providers, CDC project officers, evaluators, researchers, and others interested in the 
public health implications of HIV prevention program activities. These data can be used to 
learn from our work, inform programmatic activities, and document the progress of programs 
toward local, state and national HIV prevention goals.  DHAP’s NHM&E HIV testing data are 
used at the national and local levels for informing HIV prevention policy, program decision 
making, program monitoring, evaluation activities, research, presentations, and reports.  
 
This report includes data submitted to CDC for HIV testing funded by the following six program 
announcements:  PS 12-1201 funded all 61 health department (HD) jurisdictions for HIV 
prevention programs (category A), 34 HD jurisdictions for expanded HIV testing services for 
disproportionately affected populations (category B) and 30 HD jurisdictions for demonstration 
projects to implement and evaluate innovative, high-impact HIV prevention interventions and 
strategies (category C); PS11-1117 funded 12 HD jurisdictions with the highest number of 
people living with AIDS for enhanced HIV prevention planning (ECHPP); PS12-1210 funded 8 
HD jurisdictions to conduct HIV testing and continuum of care services among racial and ethnic 
minorities (CAPUS); PS 08-0803 directly funded CBOs in Puerto Rico and the U.S. Virgin 
Islands to provide HIV testing services; PS 10-1003 directly funded CBOs for HIV prevention 
interventions; and PS 11-1113 directly funded CBOs to implement HIV prevention projects for 
young  gay, bisexual, and other men who have sex with men (collectively referred to as MSM) 
of color and young transgender persons of color in CBOs.  
                                                          
1 Aggregate data are presented for San Francisco in Table 1 and test-level data are presented in the 
remaining tables of the 2013 annual HIV testing report. 
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HIV Testing and Care Continuum  
 
The 2013 annual HIV testing report presents data on the HIV testing and care continuum.  The 
HIV Care Continuum begins with an HIV test and the identification of an HIV-positive person, 
followed by linkage to important HIV prevention and treatment services.  This report presents 
data specifically on the HIV testing domains portrayed in the darker shade below. 
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Report Content and Organization 
 
The content of this report addresses the first three goals of the National HIV/AIDS Strategy 
(NHAS) and the DHAP Strategic Plan, specifically: 
 
 Reduce the number of persons who become HIV infected 
 Increase access to care and improve health outcomes for persons living with HIV 
 Reduce HIV-related health disparities 
 
The report also informs national HIV testing monitoring and evaluation questions for CDC-
funded HIV testing programs in 2013, including data presented by jurisdiction and by 
demographic characteristics.  Examples of these monitoring and evaluation questions include: 
 
 How many CDC-funded testing events were conducted in the United States?  
 How many persons were HIV-positive? 
 How many persons were newly identified HIV-positive? 
 What percentage of newly identified HIV-positive persons were linked to HIV medical 
care? 
 What percentage of newly identified HIV-positive persons were referred to and 
interviewed for partner services? 
 What percentage of newly identified HIV-positive persons were referred to HIV 
prevention services? 
 
This report contains 4 figures and 16 tables, which include the following: 
 
 CDC-funded HIV testing events and the continuum of HIV testing and care activities 
among newly identified HIV-positive persons 
 HIV positivity, including total number of HIV-positive persons, persons previously 
diagnosed HIV-positive, and newly identified HIV-positive persons 
 Continuum of HIV testing and care activities among newly identified HIV-positive 
persons, including data presented by test setting and target populations  
Missing/Invalid Data 
 
Missing/invalid data are important to consider when monitoring and evaluating programs.  The 
minimum percentage is calculated by including missing/invalid data in the denominator, an 
approach which underestimates performance. The maximum percentage is calculated by 
excluding missing invalid/data from the denominator, which overestimates performance.    In 
addition to providing the minimum and maximum percentages for HIV testing indicators, the 
percentages for missing/invalid data are presented. 
 
Data presented include CDC-funded HIV testing events conducted in 2013 in 61 health 
department jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands that 
were submitted to CDC as of June 2, 2014.2  To provide the most complete estimate of CDC-
funded testing events in 2013, Table 1 presents both test-level (60 health department 
                                                          
2 Data from testing events conducted in 2013 that continued to be submitted through June 2, 2014. 
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jurisdictions) and aggregate (1 health department jurisdiction – San Francisco) data.  All other 
tables display only test-level data (i.e., data for individual test records) and exclude aggregate 
data.3  Results are summarized in text, figures, and tables.  Readers are encouraged to review 
all technical notes, table titles and footnotes carefully to assist with interpretation and ensure a 
complete understanding of the data presented. 
Highlights of the 2013 Report 
HIV Testing Events  
 Approximately 3.4 million CDC-funded HIV testing events were conducted in the 61 health 
department jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands (Table 
1). 
 Of the approximately 3.4 million CDC-funded HIV testing events with test-level data, 
2,298,949 (68.8%) were conducted in health care and correctional facilities and 977,645 
(29.2%) were conducted in non-health care facilities (Table 2). 
HIV-Positive Testing Events 
 29,003 (0.9%) HIV-positive testing events were conducted in the 61 health department 
jurisdictions in the United States, Puerto Rico and the U.S. Virgin Islands (Table 1).4  
 8,561 (0.3%) of these testing events were among those who were previously diagnosed 
as HIV-positive (Table 3). 
 
Newly Identified HIV-Positive persons5 
 17,426 (0.5%) persons were newly identified HIV-positive (Table 4). 
 14,465 (0.4%) persons were newly identified confirmed HIV-positive (Table 1). 
HIV Testing and Care Continuum among Newly Identified HIV-Positive Persons6  
 91.3%–97.0% received their HIV test results. 
 49.1%–86.5% were linked to HIV medical care within 90 days7 (Table 4). 
 59.0%–77.5% were linked to HIV medical care within any timeframe8 (Table 4). 
 69.0%–85.0% were referred to partner services (Table 5). 
 50.5%–73.6% were interviewed for partner services (Table 5). 
 56.4%–78.8% were referred to HIV prevention services (Table 5). 
Missing or Invalid Data  
                                                          
3 Aggregate data were reported only for San Francisco in Table 1. 
4 Data to identify previous and newly identified positives is incomplete. 
5 Testing events cannot be reported at the person-level because one person may have received multiple 
testing events in a reporting year.  However, in this report newly identified HIV-positive testing events are 
referred to as “persons,” as a newly identified HIV positive testing event should not occur more than once 
per person.   
6  Both percentages are presented to provide a better indication of how missing/invalid data impact 
monitoring of programs. 
7 The extent to which newly identified HIV-positive persons were linked to HIV medical care within 90 days 
after initial positive test. 
8 The extent to which newly identified HIV-positive persons were linked to HIV medical care within any 
timeframe including but not limited to linkage within 90 days of initial positive test.  
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 6.0% for receipt of HIV test results. 
 43.2% for linkage to HIV medical care within 90 days (Table 4). 
 23.8% for linkage to HIV medical care within any timeframe (Table 4). 
 18.8% for referral to partner services (Table 5). 
 31.4% for interviewed for partner services (Table 5). 
 28.4% for referral to HIV prevention services (Table 5). 
 
Programmatic Impact  
 
 
 Referral to partner and HIV prevention services increased in 2013.  However, the percentage 
of newly identified HIV-positive persons linked to HIV medical care remained below the 
NHAS and DHAP Strategic Plan objective of 85%. There is need for continued improvement 
on HIV service delivery for HIV-positive persons. 
  
 Missing/invalid data across the HIV testing and continuum-of-care indicators decreased.  
Specifically, there was a lower percentage of missing data for receipt of HIV test results 
(6.0% in 2013 vs. 7.0% in 2012), linkage to HIV medical care within 90 days (43.2% in 
2013 vs. 56.0% in 2012) and interview for partner services (31.4% in 2013 vs. 44.0% in 
2012). 
   
 Continued improvement in data completeness is needed, particularly for linkage to medical 
care (i.e., linkage within 90 days and linkage within any timeframe), interview for partner 
services, and referral to HIV prevention services.  High-quality and complete data 
strengthen the ability to monitor and improve CDC-funded HIV testing programs as 
measured by these important programmatic indicators. 
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Results 
 
In 2013, 3,352,513 CDC-funded HIV testing events were conducted in the 61 health department 
jurisdictions in the United States, Puerto Rico and U.S. Virgin Islands (Table 1).   
 
More testing was conducted in health care and correctional facilities (2,298,949; 68.8%) than 
in non-health care facilities (977,645; 29.2%) (Table 2).  More than half of all tests were 
conducted in the South (1,896,334; 56.7%).   Fewer males (1,632,645; 48.8%) were tested 
than females (1,687,367; 50.5%), however males were much more likely to be newly identified 
HIV-positive (0.9%) than females (0.2%) (Table 6).   
 
By age group, the largest proportion of testing was among persons aged 20–29 years 
(1,358,687; 40.6%), and the lowest was among persons younger than 13 years (5,537; 
0.17%).  By race/ethnicity, the largest proportion of testing was among blacks/African 
Americans (1,506,016; 45%), followed by whites (901,973; 27%) and Hispanics/Latinos 
(713,058; 21.3 %).  Lastly, more than half (58.5%) of testing events used a rapid test (Table 
6).  
 
HIV-Positive Testing Events  
 
In 2013, 29,003 HIV-positive testing events were conducted, for a positivity percentage of 
0.9%.  Preliminary HIV-positive test results accounted for 4,481 (0.1%) of the total testing 
events, and confirmed HIV-positive test results accounted for 24,457 (0.7%) of the total testing 
events (Table 1).  
 
Previous HIV-Positive Testing Events 
 
Previous HIV-positive testing events accounted for 0.3% (8,561) of the total testing events, and 
of those who had previously tested HIV-positive, 4.7% (401) reported that they were already 
in HIV medical care. Houston (1.2%), Atlanta (1.1%), and Texas (0.7%), were the health 
department jurisdictions that identified the largest proportion of previously diagnosed HIV-
positive persons.  Among previously diagnosed HIV-positive persons, 93.7%–97.5% received 
their HIV test results, 45.0%–87.1% were linked to HIV medical within 90 days after diagnosis, 
and 63.0%–83.2% were linked to HIV medical care within any timeframe (Table 3). 
 
Newly Identified HIV-Positive Persons 
 
Among 2013 HIV testing events, 17,426 (0.5%) were newly identified HIV-positive (Table 4), 
of which 14,465 (83.0%) were confirmed through a valid confirmatory lab test result (Table 1).  
The remaining sections of the report present data only for newly identified HIV-positive persons, 
including both preliminary and confirmed HIV-positive persons.  
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Groups with newly identified HIV positivity percentages greater than the national average of 
0.5% were: males (0.9%), persons aged 40–49 years (0.7%), multi-racial persons (1.0%) and 
black/African American persons (0.6%). 
 
By geographic region, the highest percentages of HIV positivity were in the U.S. dependent 
areas (0.8%) and the West (0.6%).  By test setting, non-health care facilities (0.7%) had HIV 
positivity percentages greater than the national average, whereas health care facilities had a 
lower percentage (0.4%) (Table 6).  By health department jurisdiction, newly identified HIV 
positivity was highest for Atlanta (1.7%), Mississippi (1.2%), Illinois (excluding Chicago) 
(1.1%), and Arkansas (1.0%) (Table 4).  HIV positivity percentages for newly identified persons 
are displayed in Figure 1 by demographic characteristics.  
 
HIV Testing and Care Continuum for Newly Identified HIV-Positive Persons 
 
Receipt of HIV Test Results 
 
Among all newly identified HIV-positive persons, 91.3%–97.0% received their HIV test results.  
By test setting, 88.5%–96.3% received their results in health care and correctional facilities, 
compared with 96.2%–98.0% in non-health care facilities.  
  
Linkage to HIV Medical Care 
 
Because of the positive prevention and treatment benefits of early initiation of antiretroviral 
therapy, the objectives and programmatic priorities of NHAS and the DHAP Strategic Plan are to 
link all HIV-positive persons into HIV medical care within 90 days after diagnosis.  A goal of 
NHAS is to have 85% of all newly diagnosed persons linked to medical care within 90 days of 
diagnosis by 2015.  Based on a joint letter from Health Resources and Services Administration 
(HRSA) and CDC, all newly identified HIV-positive persons, including those who were preliminary 
and confirmed HIV-positive, should be linked to HIV medical care.  Given continuing program 
and data quality challenges related to health departments ascertaining and documenting linkage 
to HIV medical care within 90 days, linkage data in this report are presented for both linkage to 
HIV medical care within 90 days and linkage within any timeframe (which includes but is not 
limited to linkage within 90 days). 
 
 
 
Among newly identified HIV-positive persons, 49.1%–86.5% were linked to HIV medical care 
within 90 days after initial positive test (Table 4). Percentages for linkage to HIV medical care 
within 90 days varied when demographic characteristics and missing/invalid data were taken 
into account. 
 
 Age:  49.1%–86.5% of persons aged 20-29 years and 50.5%–88.6% of persons aged 30-
39 years were linked to HIV medical care within 90 days, and persons younger than 13 
years were least likely to be linked (20.0%-62.5%) (Table 6). 
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 Gender: Maximum linkage rates within 90 days were similar among males (49.7%–
86.5%) and females (46.5%–86.5%) (Table 6). 
 
 Test setting:  Rates of linkage within 90 days were 51.4%–86.1% among persons tested 
in health care and correctional facilities and 47.3%–87.3% among persons tested in non-
health care facilities (Tables 6, 8, 10).  
 
 Race/ethnicity:  Hispanics/Latinos (58.8%–92.4%) were linked within 90 days more than 
whites (51.5%-90.2%) and blacks/African Americans (44.5%-82.5%) (Table 6). 
 
 U.S. geographic region:  Persons in the U.S. dependent areas (82.6%–97.5%) were 
linked within 90 days more than persons in other regions, and those in the South were 
least likely to be linked (42.9%–83.9%) (Table 6). 
 
 
Among newly identified HIV-positive persons, 59.0%–77.5% were linked to HIV medical care 
within any timeframe (Table 4).  Percentages for linkage to HIV medical care within any 
timeframe varied when demographic characteristics and missing/invalid data were taken into 
account. 
 
 Age:  Persons in age groups 20–29 (59.2%–78.0%) and 30–39 (60.5%–78.7%) were 
linked within any timeframe more than persons in other age groups.  Persons younger 
than 13 years were least likely to be linked (32.0%–44.4%) (Table 6). 
 
 Gender:  Males (60.2%–77.8%) were linked within any timeframe more frequently than 
females (54.6%–76.4%) (Table 6). 
 
 Test setting:  Maximum rates of linkage within any timeframe were similar among 
persons tested in health care and correctional facilities (61.4%–77.5%) and persons 
tested in non-health care facilities (57.3%–77.7%) (Tables 6, 8, 10). 
 
 Race/ethnicity:  Hispanics/Latinos (71.1%–84.9%) were linked within any timeframe 
more than whites (62.7%–80.1%) and blacks/African Americans (53.5%–73.8%) (Table 
6). 
 
 U.S. geographic region:  Persons in the U.S. dependent areas (83.2%–87.4%) were 
linked within any timeframe more than persons in other regions, and those in the South 
were least likely to be linked (54.9%–74.6%) (Table 6). 
 
Missing/invalid data create challenges for determining true linkage percentages and addressing 
progress toward achieving the goal of 85% linkage.  Continued improvement in data 
completeness and quality is needed for linkage and for all HIV testing indicators to determine 
whether CDC-funded HIV testing programs meet the NHAS goal.  
 
Referral to Partner Services 
 
After receiving an HIV-positive test result, persons are referred to partner services.  Some 
programs may have partner services available on-site, and others may refer clients to another 
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agency or clinic.  Among all newly identified HIV-positive persons, 69.0%–85.0% were referred 
to partner services in 2013 (Table 5).  Percentages for referral to partner services varied when 
demographic characteristics and missing/invalid data were taken into account. 
 
 Age:  71.4%–86.9% of persons aged 20–29 years and 69.1%–86.3% of persons aged 30–
39 years were referred to partner services, and persons younger than 13 years were least 
likely to be referred (48.0%–52.2%) (Table 7). 
 
 Gender:  Males (69.5%–85.2%) were referred to partner services more than females 
(66.4%–84.0%) (Table 7). 
 
 Test setting:  Maximum rates of referral to partner services were similar among persons 
tested in health care and correctional facilities (68.7%–85.5%) and persons tested in non-
health care facilities (71.5%–84.6%) (Tables 7, 9, 11). 
 
 Race/ethnicity:  73.8%–87.9% of Hispanics/Latinos, 72.5%–86.7% of whites, and 
65.8%–83.7% of blacks/African Americans were referred to partner services (Table 7). 
 
 U.S. geographic region:  Persons in the U.S. dependent areas (88.9%–90.5%) were 
referred to partner services more than persons in the South (64.1%–85.1%) and in the 
Northeast (71.1%–80.1%) (Table 7). 
 
Interview for Partner Services 
 
In addition to referral to partner services, it is necessary to monitor whether persons were 
interviewed for partner services so that essential HIV services (e.g., testing, referral, and 
linkage) can be provided to both the person and his/her partner(s), as needed.  
 
Among all newly identified HIV-positive persons, 50.5%–73.6% were interviewed for partner 
services in 2013 (Table 5).  Percentages for interviewed for partner services varied when 
demographic characteristics and missing/invalid data were taken into account. 
 
 Age:  50.7%–75.3% of persons aged 20–29 years and 51.4%–74.8% of persons aged 
30–39 years were interviewed for partner services, and persons younger than 13 years 
were least likely to be interviewed (32.0%–38.1%) (Table 7). 
 
 Gender: 50.9%-73.6% of males and 49.0%-74.0% of females were interviewed for 
partner services (Table 7).  
 Test setting:  Persons tested in health care and correctional facilities (52.3%–74.6%) 
were interviewed for partner services more than persons tested in non-health care 
facilities (49.6%–72.5%) (Tables 7, 9, 11). 
 
 Race/ethnicity:  Hispanics/Latinos (60.1%–77.4%) were interviewed for partner 
services more than whites (52.4%–74.2%) and blacks/African Americans (46.4%–
72.5%) (Table 7). 
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 U.S. geographic region:  Persons in the U.S. dependent areas (79.3%–87.4%) were 
interviewed for partner services more than persons in other regions.  Persons in the 
Northeast were least likely to be interviewed (53.3%-69.7%) (Table 7). 
 
Referral to HIV Prevention Services 
 
After receiving an HIV-positive test result, persons should be referred to HIV prevention services.  
HIV prevention services include services intended to reduce the risk of transmitting or acquiring 
HIV infection (e.g. prevention counseling, evidence-based behavioral interventions, risk-
reduction counseling).  Among all newly identified HIV-positive persons, 56.4%–78.8% were 
referred to HIV prevention services in 2013 (Table 5).  Percentages for referral to HIV prevention 
services varied when demographic characteristics and missing/invalid data were taken into 
account. 
 
 Age:  58.4%–79.8% of persons aged 20–29 years and 55.3%–77.4% of persons aged 30–
39 years were referred to HIV prevention services (Table 7). 
 
 Gender:  Males (57.5%–79.2%) were referred to HIV prevention services more than 
females (52.4%–77.3%) (Table 7). 
 
 Test setting:  Rates of referral to HIV prevention services were higher among persons 
tested in health care and correctional facilities (60.2%–80.1%) than among persons tested 
in non-health care facilities (52.4%–76.5%) (Tables 7, 9, 11). 
 
 Race/ethnicity:  61.0%–77.9% Hispanics/Latinos, 58.3%–77.7% of whites and 53.6%–
79.7% of black/African Americans were referred to HIV prevention services (Table 7). 
 
 U.S. geographic region:  Persons in the Northeast (74.6%–83.4%) and in the U.S. 
dependent areas (83.5%–85.8%) were referred to HIV prevention services more than 
persons in the Midwest (58.2%–81.6%) and in the South (48.7%–76.9%) (Table 7). 
 
Target Populations 
 
Target population categories include: 1) MSM who report injection drug use, 2) MSM, 3) 
transgender persons who report injection drug use, 4) transgender persons, 5) injection drug 
use, 6) heterosexual males, and 7) heterosexual females.  The process used to create these 
categories is described further in the ‘Technical Notes’ section.   
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These categories are mutually exclusive and were 
calculated on the basis of the person’s gender and self-
reported sexual behavior of the person.   
 
Approximately 10% (346,717) of all CDC-funded testing 
events were conducted among MSM, transgender, and 
persons who report injection drug use (Table 6).   
 
 
The data for the HIV testing and care continuum are 
presented below for select target populations from both 
health care and non-health care facilities, as target population data are required for all HIV 
positive persons. This is followed by more detailed information for MSM and heterosexual 
females tested in non-health care facilities. 
 
 Linkage to HIV medical care in 90 days:  60.7%–88.3% of MSM, 50.0%–86.2% of 
transgender persons, and 54.1%–86.8% of heterosexual females were linked in 90 days 
(Table 6). 
 
 Linkage to HIV medical care within any timeframe:  66.4%–80.2% of MSM, 57.0%–
75.0% of transgender persons, and 58.2%–78.0% of heterosexual females were linked 
within any timeframe (Table 6). 
 
 Referral to partner services:  82.9%–89.3% of MSM, 71.0%–81.6% of transgender 
persons, and 76.6%–86.7% of heterosexual females were referred to partner services 
(Table 7). 
 
 Interview for partner services:  62.1%–77.7% of MSM, 48.5%–69.8% transgender 
persons, and 57.2%–77.5% of heterosexual females were interviewed for partner 
services (Table 7). 
 
 Referral to HIV prevention services:  69.3%–81.3% of MSM, 54.0%–72.5% of 
transgender persons, and 59.8%–78.0% of heterosexual females were referred to HIV 
prevention services (Table 7). 
 
Men Who Have Sex with Men (MSM) 
 
In 2013, 153,274 testing events were conducted among MSM in non-health care facilities 
(Table 12). Of these testing events among MSM, 3,681 (2.4%) were newly identified HIV-
positive.   
 
HIV positivity was higher for MSM tested in the South (3.2%), black/African American MSM 
(4.7%), and MSM aged 20-29 years (2.8%) and 30-39 years (2.4%).  Linkage to HIV medical 
care percentages among MSM varied by certain demographic characteristics (Table 12): 
 
 Persons aged 20-29 years:  56.5%–89.9%were linked within 90 days, and 62.1%–
79.3% were linked within any timeframe.  
 
Data to classify persons into 
one of these categories are 
required to be collected for 
all test events conducted in 
non-health care facilities and 
are only required to be 
collected for HIV-positive 
persons in health care 
facilities.   
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 Persons aged 30-39 years:  58.8%–93.5%were linked within 90 days, and 63.8%–
81.0% were linked within any timeframe.  
 
 Black/African Americans:  51.6%–86.9%were linked within 90 days, and 56.6%–73.9% 
were linked within any timeframe. 
 
 South:  57.9%–93.0% were linked within 90 days, and 62.5%–79.7%were linked within 
any timeframe. 
 
Data on referral to partner services, interview for partner services, and referral to HIV 
prevention services for newly identified HIV-positive MSM tested in non-health care facilities 
are provided in Table 13. 
Heterosexual Females 
 
In 2013, 259,963 testing events were conducted among heterosexual females in non-health 
care facilities, and of these, 753 (0.3%) were newly identified HIV-positive.  (Table 6 and 
Table 14).   
 
HIV positivity percentage was higher for females who were tested in the Northeast region 
(0.4%), 50 years and older (0.7%), aged 40-49 years (0.6%), and black/African American 
(0.4%).  Linkage to HIV medical care percentages among heterosexual females varied by 
demographic characteristics (Table 14): 
 
 Females aged 40-49 years:  46.1%–79.8% were linked within 90 days, and 49.0%–
65.6% were linked within any timeframe. 
 
 Females aged 50 years and older:  47.9%–78.0% were linked within 90 days, and 
52.8%–71.1% were linked within any timeframe. 
 
 Black/African Americans:  50.4%–82.7% were linked within 90 days, and 53.3%–73.9% 
were linked within any timeframe. 
 
 Northeast: 55.5%–92.2% were linked within 90 days, and 57.0%–75.3% were linked 
within any timeframe. 
 
Data on referral to partner services, interview for partner services, and referral to HIV 
prevention services for newly identified HIV-positive heterosexual females tested in non-health 
care facilities are provided in Table 15. 
 
Conclusions  
 
Beginning in 2012, significant changes were made to the annual HIV testing report in order to 
align with programmatic priorities for CDC-funded HIV testing programs.  For example, to better 
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monitor progress towards important national prevention program goals, the annual report now 
focuses on all newly identified HIV-positive persons rather than only on newly identified 
confirmed HIV-positive persons.  This change was made largely as a result of policy and 
programmatic changes. In February 2013 a joint letter from CDC and HRSA emphasized the 
importance of all persons identified as HIV-positive being linked to HIV medical care in a timely 
manner, regardless of whether they had received a preliminary or confirmed HIV-positive test 
result.  Since the advent of treatment as prevention, timely linkage to HIV medical care has 
become a programmatic priority to ensure better health outcomes for HIV-positive persons and 
to prevent HIV transmission to HIV-negative persons.  Although identification of new HIV-positive 
persons is critical, ensuring that all HIV-positive persons receive necessary HIV prevention, care, 
and treatment services is equally important.  Monitoring and evaluation data improvements are 
needed to better track progress toward the goals outlined by NHAS and the DHAP Strategic Plan. 
 
The amount of missing data, particularly for important linkage and referral indicators, improved 
nationally since 2012 but continues to need improvement.  Missing data result from jurisdictions 
not collecting or not submitting all required data elements.   Overall, receipt of HIV test result 
had the least missing/invalid data (6%), followed by referral to partner services (19%), linkage 
to HIV medical care within any timeframe (24%), and referral to HIV prevention services (28%).  
Linkage to HIV medical care within 90 days had the highest percentage of missing/invalid data 
(43%) (Tables 4 and 5).  Without complete data, it is difficult to monitor and evaluate CDC-
funded HIV-testing program progress toward key NHAS and DHAP targets.  Jurisdictions should 
continue to strive for more complete data submission to CDC’s NHM&E system so that CDC-
funded HIV testing programs can be effectively monitored and evaluated.   
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Technical Notes 
National HIV Prevention Monitoring and Evaluation HIV Testing Data Collection 
 
The 2013 NHM&E HIV testing data were submitted to CDC by health department and community-
based organization (CBO) grantees through EvaluationWeb.  Health departments and CBOs are 
required to submit data a minimum of twice annually (March and September).  This report 
includes all testing events occurring in 2013 that were reported to CDC by June 2, 2014. 
 
NHM&E data are submitted to CDC in a standard format.  A data collection template including 
required data fields is provided to all jurisdictions.  Health departments and CBOs are able to 
modify this template to better meet their local programmatic needs; however, required data 
fields cannot be omitted.  
 
 
Data Quality Assurance Monitoring and Grantee Feedback 
 
The Testing Monitoring and Evaluation Team (TMET) of the Program Evaluation Branch (PEB) in 
the Division of HIV/AIDS Prevention (DHAP) is tasked with ensuring the quality and validity of 
the NHM&E HIV testing data. To meet this goal, a standardized, robust, data quality check is 
performed bi-annually after each data submission deadline.  Required data fields are checked to 
ensure minimal missing/invalid data.  Additional attention is paid to required data fields used in 
the calculation of indicators, including HIV test result received, linkage to HIV medical care within 
any timeframe, linkage to HIV medical care within 90 days, referral to partner services, interview 
for partner services, and referral to HIV prevention services.  Conference calls were scheduled 
with each health department jurisdiction to review the quality of the data, to allow for discussion 
of any areas for improvement, and to provide TA on high-priority data fields requiring edits or 
updates. 
 
Additionally, grantees are encouraged to develop and use local data quality assurance protocols 
and procedures to improve and maintain high-quality data. As required in CDC program 
announcements that support testing activities, all CDC grantees must put in place processes to 
ensure programmatic quality (e.g., providing HIV test results to persons, promptly and linking 
HIV-positive persons to HIV medical care).  
 
Interpretation of HIV Testing Data 
 
When interpreting data in this report, several points should be considered. 
  
 Significant changes were made to the calculations of the HIV testing indicators from 
previous reports.  Therefore, comparability with previous annual HIV testing reports on 
several indicators may be limited.  However, to support comparability, Table 16 applies 
these new calculations to each of the indicators for years 2011-2013.  These changes will 
be described further in the next section, “Definitions.” Table 16 shows the number and 
percentages for HIV testing events, HIV-positive testing events, newly identified HIV-
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positive persons, and linkage to HIV medical care within any time frame by demographic 
characteristics from 2011-2013.   
 
 Some findings may be influenced by whether testing sites more commonly promoted 
routine or targeted HIV testing.  For example, the number of HIV testing events may be 
lower in geographic areas or jurisdictions with targeted testing focused on certain high-
risk populations, and correspondingly, the HIV positivity in these areas or jurisdictions 
may be higher.  
 
 The population accessing HIV testing services at publicly funded sites is not necessarily 
representative of all persons who are tested in the United States.  This report does not 
include information about HIV testing services that were supported by the Departments 
of Defense, Justice, Labor, and Veterans Affairs, Centers for Medicare and Medicaid 
Services, Health Resources and Services Administration, Substance Abuse and Mental 
Health Services Administration, agencies of the U.S. Public Health Service other than CDC, 
state and local health departments, and the private sector.  However, it is possible that 
some of these testing events may be included, if they were not categorized under the 
correct funding announcement when the data were submitted to CDC.  
 
 It is not possible to link the results of repeat HIV testing events for the same person in 
the same year.   
  
 HIV testing data are collected by HIV prevention program activities in conjunction with 
delivery of other health services.  Therefore, the comparability of these data across health 
department jurisdictions may be limited due to differences in data collection, quality 
assurance, or quality improvement activities that occur at the state or local levels.  
Comparability within a health department jurisdiction may also be limited for the same 
reasons.  
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Definitions 
 
Age 
 
The age of the person at testing, as determined by calculating the difference between the 
year of a person’s birth and the year of the HIV testing session. 
 
Data designation 
 
Aggregate data 
Total HIV testing events and confirmed HIV-positive testing events reported by health 
department jurisdictions when complete test-level data were not submitted to CDC.   
 
Invalid data 
Any test-level data submitted by the health department jurisdiction that do not conform 
to the value codes stated in the NHM&E data variable set (DVS).  
 
Missing data 
Any required data associated with a valid HIV testing record for which data were not 
submitted by the health department jurisdiction.  These data were either not collected 
by the health department jurisdiction or were collected but not reported to CDC. 
 
Test-event level data 
Data reported by health department jurisdictions for each HIV testing event conducted, 
including demographics, HIV testing event data, and when appropriate, behavioral risk, 
linkage to HIV medical care (within 90 days and within any timeframe), referral to and 
interview for partner services and referral to HIV prevention services data.   
 
Data variable set  
 
Data dictionary with all NHM&E data elements, including mandatory, required, and allowed 
data elements.  Information provided in the DVS includes variable number, name, schema 
name, format type, minimum and maximum length, value codes, instructions, and definitions.  
 
Gender 
 
The person’s self-reported current gender identity and may include one’s social status, self-
identification, legal status, and biology.  Current gender identity is submitted to CDC as male, 
female, male-to-female transgender (i.e., a person whose physical or birth sex is male, but 
whose gender expression and/or gender identity is female), or female-to-male transgender 
(i.e., a person whose physical or birth sex is female, but whose gender expression and/or 
gender identity is male).  Additionally, in order to identify transgender persons, sex at birth 
and current gender identity are examined.  If the self-reported genders do not match, the 
person is classified as a transgender person.   
 
For this report, gender is reported as male or female.  Transgender persons are reported 
under target populations (defined later in this section). 
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Interview for partner services 
 
Partner services include a range of available services for newly and previously diagnosed HIV-
positive persons, their partners, and affected communities.  Services may include: informing 
current and past sex partners that a person who is HIV-positive has identified them as a sex 
or injection-drug-paraphernalia-sharing partner and advising them to have HIV counseling 
and testing.  Additionally, it can include notifying partners, who may not have suspected that 
they were at increased risk for HIV so that they can be tested for HIV. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were interviewed for partner services.  For this report, the minimum percentage includes 
missing/invalid data in the denominator and includes all newly identified HIV-positive persons.  
The maximum percentage excludes missing/invalid data from the denominator.  
 
Linkage to HIV medical care within 90 days 
 
HIV medical care includes medical services for HIV infection, including evaluation of immune 
system function and screening, treatment, and prevention of opportunistic infections.  
Because of the importance of linking HIV-positive persons to HIV medical care in a timely 
manner, this indicator is examined separately from “linkage to HIV medical care within any 
timeframe.”  
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were linked to HIV medical care within 90 days after initial positive test.  In order for a person 
to be linked to care, the person must have attended the first medical care appointment within 
90 days after the initial HIV testing session.  For this report, the minimum percentage includes 
missing/invalid data in the denominator and includes all newly identified HIV-positive persons.  
The maximum percentage excludes missing/invalid data from the denominator.  
 
Linkage to HIV medical care within any timeframe 
 
HIV medical care includes medical services for HIV infection, including evaluation of immune 
system function and screening, treatment, and prevention of opportunistic infections. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were linked to HIV medical care.  In order for a person to be considered linked to HIV medical 
care within any timeframe, the person must have attended the first medical care appointment, 
regardless of when the appointment occurred.  Linkage to HIV medical care within any 
timeframe includes persons who were linked within 90 days as well those who were linked 
after the 90-day period.  For this report, the minimum percentage includes missing/invalid 
data in the denominator and includes all newly identified HIV-positive persons.  The maximum 
percentage excludes missing/invalid data from the denominator.  
 
 
 
Race/ethnicity 
 
Race is defined as a person’s self-reported classification of the biological heritage with which 
they most closely identify.  Ethnicity is defined as a person’s self-report of whether they are 
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Hispanic or Latino.  Up to five races and one ethnicity (i.e., Hispanic or Latino) for a person 
are allowed and submitted to CDC as separate variables.  For this report, a “race/ethnicity” 
variable was created by combining the race and ethnicity variables using the following 
categories: 
 Hispanic or Latino (“Hispanic or Latino” in the ethnicity variable regardless of the race 
variables) 
 Remaining persons who selected “Not Hispanic or Latino” for the ethnicity variable 
were categorized as: 
 White  
 Black or African American 
 Asian 
 American Indian or Alaska Native 
 Native Hawaiian or Pacific Islander 
 Multi-race (persons who selected more than one race) 
 Declined 
 Don’t know 
 Invalid 
 Missing 
 
Rapid test used in testing event  
 
This calculated variable indicates whether rapid testing technology was used for an HIV test.  
A response of “yes” indicates that at least one test within a testing event was performed by 
using a rapid test technology.  
  
 
Referral to HIV prevention services 
 
HIV prevention services are defined as any service or intervention directly aimed at reducing 
the risk of transmitting or acquiring HIV infection (e.g., prevention counseling, effective 
behavioral interventions, risk-reduction counseling). HIV posttest counseling and indirect 
services, such as mental health services or housing, are excluded. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were provided with a referral to HIV prevention services.  For this report, the minimum 
percentage includes missing/invalid data in the denominator and includes all newly identified 
HIV-positive persons.  The maximum percentage excludes missing/invalid data from the 
denominator.  
 
Referral to partner services 
 
Partner services include a range of available services for newly and previously diagnosed HIV-
positive persons, their partners, and affected communities.  Services may include informing 
current and past sex partners that a person who is HIV-positive has identified them as a sex 
or injection-drug-paraphernalia-sharing partner and advising them to have HIV counseling 
and testing.  Additionally, it can include notifying partners, who may not have suspected that 
they were at increased risk of HIV so that they can be tested for HIV. 
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This calculated indicator measures the extent to which newly identified HIV-positive persons 
were provided with a referral to partner services.  For this report, the minimum percentage 
includes missing/invalid data in the denominator and includes all newly identified HIV-positive 
persons.  The maximum percentage excludes missing/invalid data from the denominator.  
 
 
Results received 
 
This calculated indicator measures the extent to which persons received HIV test results from 
the initial testing site or obtained the results from another agency for at least one HIV test in 
the testing event, regardless of the HIV test technology or how many tests were conducted.  
For this report, the minimum percentage includes missing/invalid data in the denominator 
and includes all newly identified HIV-positive persons.  The maximum percentage excludes 
missing/invalid data from the denominator.  
 
 
Target populations 
 
NHM&E data for target populations are collected from the person for behavior during the 12 
months before the HIV test.  The collection of these data is required for all tests performed 
in non-health care facilities and for HIV-positive persons in health care facilities.  For this 
report, mutually exclusive target populations are determined for HIV-positive persons by 
using a combination of behaviors and gender of the person (male, female, and transgender).  
The behaviors used to calculate the target populations include vaginal or anal sex with males 
or females and use of injection drugs. 
 
The target populations are ordered hierarchically on the basis of the most likely presumed 
risk for exposure to HIV as follows: 
 
 Men who have sex with men and report injection drug use: includes males who reported 
both male-to-male sexual contact and injection drug use in the past 12 months 
 
 Men who have sex with men: includes males who reported male-to-male sexual contact 
in the past 12 months 
 
 Transgender persons who report injection drug use: includes transgender persons (i.e., 
persons who self-reported current gender as transgender or self-reported sex at birth 
is different from self-reported current gender) who reported injection drug use in the 
past 12 months 
 
 Transgender person: includes persons who self-reported current gender as transgender 
or persons whose self-reported gender at birth is different from self-reported current 
gender 
 
 Injection drug use:  includes persons who reported injection drug use in the past 12 
months 
 
 Heterosexual male:  includes males who only reported heterosexual contact with a 
female in the past 12 months 
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 Heterosexual female:  includes females who only reported heterosexual contact with a 
male in the past 12 months 
 
 Missing/invalid: includes persons: (1) who did not report any of these behaviors, (2) 
who were not asked about these behaviors, (3) who declined to discuss these behaviors, 
or (4) for whom these data were not reported, even though they were asked about 
these behaviors 
 
 
Testing events 
 
HIV testing event 
An HIV testing event is one or more HIV tests performed with a person to determine a 
person’s HIV status. During one testing event, a person may be tested once (e.g., one 
rapid test or one conventional test) or multiple times (e.g., one rapid test followed by 
one conventional test to confirm a preliminary HIV-positive test result).  
 
Invalid HIV testing event 
An HIV testing event is considered invalid if data are missing/invalid for all of the tests 
that comprise that HIV testing event for both the following variables: test technology 
(i.e., conventional, rapid, or other) or HIV test result (i.e., negative, positive, 
indeterminate, invalid, or no result).  These records (0.5% of the total records for 2013) 
are not included in this report.  
 
Testing record 
 
Invalid testing record 
Required data within a valid HIV testing record that do not conform to the data structure 
specified by CDC (e.g., illogical dates (02/30/2013), incomplete dates (02/2013), future 
years, unacceptable value codes, or unexpected data based upon skip patterns in the 
data collection form). 
 
Valid HIV testing record 
A test-level data record that includes the mandatory data fields of: session date, agency 
ID, intervention ID, site ID, site type, and client ID.  A test-level testing record cannot 
be submitted without the mandatory data fields. 
 
 
Test results  
 
Confirmed HIV-positive testing event 
A testing event with an HIV-positive test result for a conventional HIV test (positive 
enzyme immunoassay (EIA) test confirmed by supplemental testing, e.g., Western blot) 
or a nucleic acid amplification test (NAAT).  For the purposes of the 2013 annual HIV 
testing report and for monitoring and evaluation purposes only, two rapid tests were 
categorized as a confirmed HIV-positive testing event, unless a negative conventional 
HIV test result or a negative NAAT test result was documented in the same test event. 
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HIV-positive testing event 
An HIV-positive testing event is determined by any of the following test results: (1) a 
NAAT/RNA positive test result, (2) a conventional positive test result if a negative 
NAAT/RNA test result was not part of that testing event, (3) a rapid positive test result 
if a negative NAAT/RNA or negative conventional test result was not part of that testing 
event, and (4) a documented positive test result, even if test technology data are  
missing/invalid if a negative NAAT/RNA or negative conventional test result was not part 
of that testing event. 
 
Newly identified HIV-positive person  
An HIV-positive test result associated with a person who reports: (1) no previous HIV 
test, (2) a previous HIV test with a negative or an indeterminate result, or (3) “don’t 
know” for previous HIV test result.  
 
Preliminary HIV-positive testing event 
A testing event with an HIV-positive test result from one rapid HIV test or an HIV-positive 
test result for which test technology is missing/invalid, without another documented HIV-
positive test result. 
 
Previous HIV-positive person 
A person who self-reports having a previous positive HIV test result. 
 
 
Test setting 
  
Test setting is determined by the site type where HIV testing is provided, and for this 
report, it is classified into the following categories: 
 
 Health care and correctional facilities:  inpatient facilities, outpatient facilities, 
emergency rooms, and correctional facilities 
 
 Non-health care facilities:  HIV counseling and testing sites and community settings 
 
 Other facilities: blood banks/plasma centers and any other facilities not previously 
listed 
 
 Invalid: the site code submitted for the facility is not one of the acceptable site codes 
 
 Missing:  no site code is submitted for the testing event 
 
U.S. geographic region 
    
The U.S. geographic regions are as follows: 
 
 Northeast:  Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New 
York, Pennsylvania, Rhode Island, and Vermont 
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 Midwest:  Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, 
North Dakota, Ohio, South Dakota, and Wisconsin 
 
 South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, 
Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South 
Carolina, Tennessee, Texas, Virginia, and West Virginia 
 
 West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New 
Mexico, Oregon, Utah, Washington, and Wyoming 
 
 U.S. dependent areas:  Puerto Rico and U.S. Virgin Islands 
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Figure 1. Newly identified HIV positivity percentages by characteristics of persons tested, 61 health department 
jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013.  
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The newly identified positivity percentage in the 61 health 
department jurisdictions submitting test-level NHM&E data 
in the United States, Puerto Rico, and the U.S. Virgin Islands 
in 2013 was .5% (17,426/3,343,633), as depicted by the 
dash line.
Blue bars indicate demographic characteristicsc in which the 
HIV positivity percentage is greater than .5%.
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American Indian/Alaska Natives and Native Hawaiian/Pacific Islanders are omitted due to the small number of newly identified HIV-positive persons. 
Please refer to Table 6 for figure data. 
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Figure 2. HIV testing and care continuum indicators among newly identfied HIV-positive persons, 61 health department 
jurisdictions in the United States, Puerto Rico, and the U. S. Virgin Islands, 2013.  
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Linked to HIV medical care in 90 days (maximum): 86.5%
Linked to HIV medical care within any timeframe (maximum): 77.5%
Referred to partner services (maximum): 85.0%
Interviewed for partner services (maximum): 73.6%
Referred to HIV prevention services (maximum): 78.8%
Maximum indicator percentages exclude missing data from the denominator.  Minimum percentages include missing data in the denominator.  Please refer to Tables 4-7 for figure data.  Note:  The 
maximum percentage for linkage to HIV medical care within 90 days is greater than the maximum percentage for linkage within any timeframe due to the higher percentage of missing/invalid data for linkage 
within 90 days. 
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Figure 3. HIV testing and care continuum indicators among newly identfied HIV-positive men who have sex with men 
(MSM) in non-health care facilities, 61 health department jurisdictions in the United States, Puerto Rico, and the US. 
Virgin Islands, 2013   
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Referred to partner services (maximum): 85.9%
Interviewed for partner services (maximum): 73.7%
Referred to HIV prevention services (maximum): 77.9%
Maximum indicator percentages exclude missing data from the denominator.  Minimum percentages include missing data in the denominator.  Please refer to Tables 12-13 for figure data.  Note:  The 
maximum percentage for linkage to HIV medical care within 90 days is greater than the maximum percentage for linkage within any timeframe due to the higher percentage of missing/invalid data for linkage 
within 90 days. 
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 Figure 4. HIV testing and care continuum indicators among newly identfied HIV-positive heterosexual females in non-
health care facilities, 61 health department jurisdictions in the United States, Puerto Rico, and the U. S. Virgin Islands, 
2013. 
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Maximum indicator percentages exclude missing data from the denominator.  Minimum percentages include missing data in the denominator.  Please refer to Tables 14-15 for figure data.  Note:  The 
maximum percentage for linkage to HIV medical care within 90 days is greater than the maximum percentage for linkage within any timeframe due to the higher percentage of missing/invalid data for 
linkage within 90 days. 
32 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Tables
33 
 
 
 
Table 1. Number of HIV testing events and HIV positivity by 61 CDC-funded jurisdictions, United States,     
Puerto Rico, and the U.S. Virgin Islands, 2013. 
CDC-funded jurisdiction 
HIV testing 
events 
HIV-positive 
testing 
events 
Preliminary HIV-
positive testing 
events 
Confirmed HIV-
positive 
testing events 
Newly identified 
HIV-positive 
testing events 
Newly identified 
confirmed HIV-
positive 
testing events 
No. No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) 
Alabama 94,968 1,126 (1.2) 284 (0.3) 842 (0.9) 448 (0.5) 302 (0.3) 
Alaska 2,244 6 (0.3) 0 (0.0) 6 (0.3) 5 (0.2) 5 (0.2) 
Arizona 38,802 368 (0.9) 38 (0.1) 330 (0.9) 279 (0.7) 249 (0.6) 
Arkansas 32,087 379 (1.2) 37 (0.1) 342 (1.1) 330 (1.0) 302 (0.9) 
California            
   Los Angeles 125,080 1,282 (1.0) 397 (0.3) 885 (0.7) 1,040 (0.8) 748 (0.6) 
   San Franciscoa 45,119 613 (1.1) -- -- 548 (0.9) 79 (0.2) -- -- 
   California (excludes Los Angeles 
and San Francisco) 
118,712 673 (0.6) 161 (0.1) 512 (0.4) 509 (0.4) 392 (0.3) 
Colorado 23,171 185 (0.8) 9 (0.0) 176 (0.8) 87 (0.4) 84 (0.4) 
Connecticut 51,658 212 (0.4) 47 (0.1) 165 (0.3) 129 (0.2) 115 (0.2) 
Delaware 11,290 48 (0.4) 13 (0.1) 35 (0.3) 41 (0.4) 33 (0.3) 
District of Columbia 123,707 598 (0.5) 454 (0.4) 144 (0.1) 479 (0.4) 120 (0.1) 
Florida 425,689 4,335 (1.0) 382 (0.1) 3,953 (0.9) 2,531 (0.6) 2,294 (0.5) 
Georgia            
   Atlanta 37,123 1,057 (2.8) 104 (0.3) 953 (2.6) 627 (1.7) 557 (1.5) 
   Georgia (excludes Atlanta) 81,534 400 (0.5) 54 (0.1) 346 (0.4) 309 (0.4) 272 (0.3) 
Hawaii 10,247 34 (0.3) 3 (0.0) 31 (0.3) 31 (0.3) 29 (0.3) 
Idaho 3,582 8 (0.2) 2 (0.1) 6 (0.2) 5 (0.1) 5 (0.1) 
Illinois            
   Chicago 68,900 641 (0.9) 119 (0.2) 522 (0.8) 313 (0.5) 243 (0.4) 
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CDC-funded jurisdiction 
HIV testing 
events 
HIV-positive 
testing 
events 
Preliminary HIV-
positive testing 
events 
Confirmed HIV-
positive 
testing events 
Newly identified 
HIV-positive 
testing events 
Newly identified 
confirmed HIV-
positive 
testing events 
No. No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) 
   Illinois (excludes Chicago) 7,147 90 (1.3) 6 (0.1) 84 (1.2) 80 (1.1) 74 (1.0) 
Indiana 13,960 100 (0.7) 6 (0.0) 94 (0.7) 89 (0.6) 84 (0.6) 
Iowa 5,100 33 (0.6) 2 (0.0) 31 (0.6) 31 (0.6) 29 (0.6) 
Kansas 19,698 46 (0.2) 1 (0.0) 45 (0.2) 43 (0.2) 42 (0.2) 
Kentucky 26,535 142 (0.5) 28 (0.1) 114 (0.4) 124 (0.5) 100 (0.4) 
Louisiana 94,891 1,097 (1.2) 49 (0.1) 1,048 (1.1) 318 (0.3) 282 (0.3) 
Maine 2,838 13 (0.5) 2 (0.1) 11 (0.4) 7 (0.2) 6 (0.2) 
Maryland            
   Baltimore 48,440 534 (1.1) 47 (0.1) 487 (1.0) 428 (0.9) 399 (0.8) 
   Maryland (excludes Baltimore) 46,572 354 (0.8) 159 (0.3) 195 (0.4) 225 (0.5) 166 (0.4) 
Massachusetts 65,492 368 (0.6) 149 (0.2) 219 (0.3) 101 (0.2) 64 (0.1) 
Michigan 72,860 482 (0.7) 430 (0.6) 52 (0.1) 385 (0.5) 29 (0.0) 
Minnesota 13,180 110 (0.8) 42 (0.3) 68 (0.5) 91 (0.7) 60 (0.5) 
Mississippi 91,854 1,390 (1.5) 47 (0.1) 1,343 (1.5) 1,128 (1.2) 1,093 (1.2) 
Missouri 85,650 524 (0.6) 56 (0.1) 468 (0.5) 183 (0.2) 159 (0.2) 
Montana 2,237 7 (0.3) 4 (0.2) 3 (0.1) 6 (0.3) 3 (0.1) 
Nebraska 9,157 33 (0.4) 10 (0.1) 23 (0.3) 27 (0.3) 20 (0.2) 
Nevada 23,477 261 (1.1) 9 (0.0) 252 (1.1) 208 (0.9) 203 (0.9) 
New Hampshire 903 4 (0.4) 0 (0.0) 4 (0.4) 3 (0.3) 3 (0.3) 
New Jersey 46,282 487 (1.1) 142 (0.3) 345 (0.7) 305 (0.7) 211 (0.5) 
New Mexico 11,117 67 (0.6) 9 (0.1) 58 (0.5) 59 (0.5) 50 (0.4) 
New York            
   New York City 125,711 902 (0.7) 107 (0.1) 795 (0.6) 722 (0.6) 671 (0.5) 
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CDC-funded jurisdiction 
HIV testing 
events 
HIV-positive 
testing 
events 
Preliminary HIV-
positive testing 
events 
Confirmed HIV-
positive 
testing events 
Newly identified 
HIV-positive 
testing events 
Newly identified 
confirmed HIV-
positive 
testing events 
No. No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) 
   New York (excludes New York City) 136,063 891 (0.7) 87 (0.1) 804 (0.6) 563 (0.4) 500 (0.4) 
North Carolina 210,364 804 (0.4) 21 (0.0) 783 (0.4) 504 (0.2) 492 (0.2) 
North Dakota 4,134 5 (0.1) 0 (0.0) 5 (0.1) 5 (0.1) 5 (0.1) 
Ohio 60,479 365 (0.6) 142 (0.2) 223 (0.4) 309 (0.5) 193 (0.3) 
Oklahoma 20,767 171 (0.8) 21 (0.1) 150 (0.7) 116 (0.6) 98 (0.5) 
Oregon 11,774 77 (0.7) 0 (0.0) 77 (0.7) 72 (0.6) 72 (0.6) 
Pennsylvania            
   Pennsylvania (excludes 
Philadelphia) 
69,411 320 (0.5) 14 (0.0) 306 (0.4) 276 (0.4) 263 (0.4) 
   Philadelphia 93,181 662 (0.7) 153 (0.2) 509 (0.5) 428 (0.5) 366 (0.4) 
Rhode Island 4,180 31 (0.7) 18 (0.4) 13 (0.3) 24 (0.6) 10 (0.2) 
South Carolina 72,857 656 (0.9) 178 (0.2) 478 (0.7) 203 (0.3) 86 (0.1) 
South Dakota 1,400 11 (0.8) 2 (0.1) 9 (0.6) 6 (0.4) 5 (0.4) 
Tennessee 140,150 1,099 (0.8) 136 (0.1) 963 (0.7) 788 (0.6) 706 (0.5) 
Texas            
   Houston 67,212 1,053 (1.6) 15 (0.0) 1,038 (1.5) 111 (0.2) 105 (0.2) 
   Texas (excludes Houston) 195,330 2,720 (1.4) 167 (0.1) 2,553 (1.3) 1,318 (0.7) 1,249 (0.6) 
Utah 9,007 52 (0.6) 9 (0.1) 43 (0.5) 45 (0.5) 40 (0.4) 
Vermont 898 5 (0.6) 0 (0.0) 5 (0.6) 4 (0.4) 4 (0.4) 
Virginia 73,196 325 (0.4) 30 (0.0) 295 (0.4) 283 (0.4) 260 (0.4) 
Washington 14,292 201 (1.4) 17 (0.1) 184 (1.3) 127 (0.9) 116 (0.8) 
West Virginia 1,768 4 (0.2) 1 (0.1) 3 (0.2) 3 (0.2) 2 (0.1) 
Wisconsin 13,539 123 (0.9) 25 (0.2) 98 (0.7) 97 (0.7) 81 (0.6) 
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CDC-funded jurisdiction 
HIV testing 
events 
HIV-positive 
testing 
events 
Preliminary HIV-
positive testing 
events 
Confirmed HIV-
positive 
testing events 
Newly identified 
HIV-positive 
testing events 
Newly identified 
confirmed HIV-
positive 
testing events 
No. No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) 
Wyoming 5,027 6 (0.1) 0 (0.0) 6 (0.1) 6 (0.1) 6 (0.1) 
Puerto Rico 35,289 408 (1.2) 34 (0.1) 374 (1.1) 328 (0.9) 305 (0.9) 
U.S. Virgin Islands 5,181 5 (0.1) 2 (0.0) 3 (0.1) 5 (0.1) 3 (0.1) 
Total 3,352,513 29,003 (0.9) 4,481 (0.1) 24,457 (0.7) 17,426 (0.5) 14,465 (0.4) 
a Data from San Francisco were reported at the aggregate level only for Table 1, which added  8,880 testing events, 321 total HIV positive testing events, 267 confirmed HIV-positive testing 
events, and excluded 11 preliminary HIV-positive testing events, and 72 newly identified confirmed HIV-positive testing events that are included in the remaining tables, which display test-
level data.  
 
37 
 
 
 
Table 2. Number of HIV testing events and newly identified HIV positivity percentages by 
test setting for 61 CDC-funded health department jurisdictions submitting test-level data 
in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Health department 
Health care and correctional facilities Non-health care facilities 
HIV testing events 
Newly HIV-positive 
testing events HIV testing events 
Newly HIV-positive 
testing events 
No. (%) No. 
(Newly 
positive 
%) No. (%) No. 
(Newly 
positive 
%) 
Alabama 37,328 (39.3) 222 (0.6) 10,754 (11.3) 52 (0.5) 
Alaska 181 (8.1) 0 (0.0) 2,063 (91.9) 5 (0.2) 
Arizona 25,431 (65.5) 222 (0.9) 13,371 (34.5) 57 (0.4) 
Arkansas 30,018 (93.6) 304 (1.0) 1,773 (5.5) 26 (1.5) 
California         
   Los Angeles 57,857 (46.3) 446 (0.8) 67,223 (53.7) 594 (0.9) 
   San Francisco 29,493 (81.4) 47 (0.2) 6,746 (18.6) 32 (0.5) 
   California (excludes Los Angeles and 
San Francisco) 
97,589 (82.2) 356 (0.4) 21,123 (17.8) 153 (0.7) 
Colorado 19,386 (83.7) 53 (0.3) 3,785 (16.3) 34 (0.9) 
Connecticut 37,980 (73.5) 87 (0.2) 13,678 (26.5) 42 (0.3) 
Delaware 7,034 (62.3) 25 (0.4) 4,256 (37.7) 16 (0.4) 
District of Columbia 118,431 (95.7) 369 (0.3) 5,276 (4.3) 110 (2.1) 
Florida 252,084 (59.2) 1,127 (0.4) 173,302 (40.7) 1,403 (0.8) 
Georgia         
   Atlanta 20,987 (56.5) 266 (1.3) 16,136 (43.5) 361 (2.2) 
   Georgia (excludes Atlanta) 73,394 (90.0) 235 (0.3) 8,140 (10.0) 74 (0.9) 
Hawaii 5,002 (48.8) 10 (0.2) 5,245 (51.2) 21 (0.4) 
Idaho 1,398 (39.0) 5 (0.4) 2,184 (61.0) 0 (0.0) 
Illinois         
   Chicago 48,034 (69.7) 176 (0.4) 10,037 (14.6) 115 (1.1) 
   Illinois (excludes Chicago) 1,364 (19.1) 21 (1.5) 5,782 (80.9) 59 (1.0) 
Indiana 7,644 (54.8) 31 (0.4) 6,316 (45.2) 58 (0.9) 
Iowa 3,722 (73.0) 28 (0.8) 1,369 (26.8) 3 (0.2) 
Kansas 17,422 (88.4) 27 (0.2) 2,276 (11.6) 16 (0.7) 
Kentucky 21,735 (81.9) 97 (0.4) 4,800 (18.1) 27 (0.6) 
Louisiana 79,292 (83.6) 97 (0.1) 15,496 (16.3) 219 (1.4) 
Maine 1,207 (42.5) 3 (0.2) 1,631 (57.5) 4 (0.2) 
Maryland         
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Health department 
Health care and correctional facilities Non-health care facilities 
HIV testing events 
Newly HIV-positive 
testing events HIV testing events 
Newly HIV-positive 
testing events 
No. (%) No. 
(Newly 
positive 
%) No. (%) No. 
(Newly 
positive 
%) 
   Baltimore 34,174 (70.5) 210 (0.6) 13,048 (26.9) 201 (1.5) 
   Maryland (excludes Baltimore) 26,161 (56.2) 143 (0.5) 19,776 (42.5) 81 (0.4) 
Massachusetts 52,783 (80.6) 94 (0.2) 12,709 (19.4) 7 (0.1) 
Michigan 62,541 (85.8) 288 (0.5) 10,319 (14.2) 97 (0.9) 
Minnesota 10,280 (78.0) 78 (0.8) 2,900 (22.0) 13 (0.4) 
Mississippi 87,892 (95.7) 1,095 (1.2) 3,958 (4.3) 32 (0.8) 
Missouri 74,040 (86.4) 84 (0.1) 11,607 (13.6) 99 (0.9) 
Montana 411 (18.4) 4 (1.0) 1,826 (81.6) 2 (0.1) 
Nebraska 6,746 (73.7) 12 (0.2) 2,411 (26.3) 15 (0.6) 
Nevada 13,473 (57.4) 124 (0.9) 10,004 (42.6) 84 (0.8) 
New Hampshire 826 (91.5) 3 (0.4) 77 (8.5) 0 (0.0) 
New Jersey 23,141 (50.0) 125 (0.5) 23,141 (50.0) 180 (0.8) 
New Mexico 8,877 (79.9) 54 (0.6) 2,240 (20.1) 5 (0.2) 
New York         
   New York City 62,964 (50.1) 355 (0.6) 62,689 (49.9) 361 (0.6) 
   New York (excludes New York City) 97,274 (71.5) 376 (0.4) 36,675 (27.0) 186 (0.5) 
North Carolina 47,044 (22.4) 69 (0.1) 163,318 (77.6) 434 (0.3) 
North Dakota 58 (1.4) 0 (0.0) 4,069 (98.4) 5 (0.1) 
Ohio 42,289 (69.9) 203 (0.5) 18,190 (30.1) 106 (0.6) 
Oklahoma 16,805 (80.9) 33 (0.2) 3,962 (19.1) 83 (2.1) 
Oregon 9,063 (77.0) 62 (0.7) 2,609 (22.2) 10 (0.4) 
Pennsylvania         
   Pennsylvania (excludes Philadelphia) 56,796 (81.8) 207 (0.4) 11,296 (16.3) 59 (0.5) 
   Philadelphia 81,819 (87.8) 237 (0.3) 11,362 (12.2) 191 (1.7) 
Rhode Island 1,741 (41.7) 10 (0.6) 2,439 (58.3) 14 (0.6) 
South Carolina 64,247 (88.2) 75 (0.1) 8,610 (11.8) 128 (1.5) 
South Dakota 747 (53.4) 1 (0.1) 653 (46.6) 5 (0.8) 
Tennessee 119,496 (85.3) 652 (0.5) 20,556 (14.7) 136 (0.7) 
Texas         
   Houston 62,429 (92.9) 43 (0.1) 4,375 (6.5) 67 (1.5) 
   Texas (excludes Houston) 126,540 (64.8) 671 (0.5) 66,152 (33.9) 631 (1.0) 
Utah 4,825 (53.6) 19 (0.4) 4,182 (46.4) 26 (0.6) 
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Health department 
Health care and correctional facilities Non-health care facilities 
HIV testing events 
Newly HIV-positive 
testing events HIV testing events 
Newly HIV-positive 
testing events 
No. (%) No. 
(Newly 
positive 
%) No. (%) No. 
(Newly 
positive 
%) 
Vermont 219 (24.4) 0 (0.0) 679 (75.6) 4 (0.6) 
Virginia 61,670 (84.3) 205 (0.3) 11,526 (15.7) 78 (0.7) 
Washington 5,918 (41.4) 55 (0.9) 8,374 (58.6) 72 (0.9) 
West Virginia 1,468 (83.0) 2 (0.1) 300 (17.0) 1 (0.3) 
Wisconsin 5,176 (38.2) 13 (0.3) 8,360 (61.7) 84 (1.0) 
Wyoming 5,022 (99.9) 4 (0.1) 2 (0.0) 2 (100.0) 
Puerto Rico 25,629 (72.6) 279 (1.1) 9,660 (27.4) 49 (0.5) 
U.S. Virgin Islands 4,352 (84.0) 5 (0.1) 829 (16.0) 0 (0.0) 
Total 2,298,949 (68.8) 10,144 (0.4) 977,645 (29.2) 7,029 (0.7) 
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Table 3: HIV testing and care continuum for persons identified as previously HIV-positive for 61 health department 
jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
CDC funded jurisdiction 
HIV 
testing 
events 
Previous 
HIV positive 
testing 
events 
Already 
in HIV 
medical 
care Linkage to HIV Medical Care* Linkage to HIV Medical Care in 90 days* 
No. No. 
(Positiv
e %) No. 
(% in 
care) Linked 
Not 
linked Missing/invalid (Missing/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Alabama 94,968 281 (0.3) 0 (0.0) 109 1 171 (60.9) (38.8) (99.1) 34 4 243 (86.5) (12.1) (89.5) 
Alaska 2,244 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Arizona 38,802 66 (0.2) 14 (21.2) 38 12 2 (3.8) (73.1) (76.0) 26 4 22 (42.3) (50.0) (86.7) 
Arkansas 32,087 49 (0.2) 1 (2.0) 1 13 34 (70.8) (2.1) (7.1) 1 0 47 (97.9) (2.1) (100.0) 
California                  
   Los Angeles 125,080 202 (0.2) 5 (2.5) 164 4 29 (14.7) (83.2) (97.6) 139 1 57 (28.9) (70.6) (99.3) 
   San Francisco 36,239 184 (0.5) 2 (1.1) 158 7 17 (9.3) (86.8) (95.8) 154 2 26 (14.3) (84.6) (98.7) 
   California (excludes Los Angeles and San 
Francisco) 
118,712 142 (0.1) 5 (3.5) 91 46 0 (0.0) (66.4) (66.4) 79 24 34 (24.8) (57.7) (76.7) 
Colorado 23,171 27 (0.1) 5 (18.5) 20 2 0 (0.0) (90.9) (90.9) 18 4 0 (0.0) (81.8) (81.8) 
Connecticut 51,658 71 (0.1) 25 (35.2) 45 1 0 (0.0) (97.8) (97.8) 45 0 1 (2.2) (97.8) (100.0) 
Delaware 11,290 7 (0.1) 3 (42.9) 4 0 0 (0.0) (100.0) (100.0) 4 0 0 (0.0) (100.0) (100.0) 
District of Columbia 123,707 114 (0.1) 11 (9.6) 75 17 11 (10.7) (72.8) (81.5) 48 18 37 (35.9) (46.6) (72.7) 
Florida 425,689 1,686 (0.4) 1 (0.1) 1,495 0 190 (11.3) (88.7) (100.0) 1,495 0 190 (11.3) (88.7) (100.0) 
Georgia                  
   Atlanta 37,123 425 (1.1) 5 (1.2) 156 250 14 (3.3) (37.1) (38.4) 145 215 60 (14.3) (34.5) (40.3) 
   Georgia (excludes Atlanta) 81,534 90 (0.1) 6 (6.7) 48 13 23 (27.4) (57.1) (78.7) 40 9 35 (41.7) (47.6) (81.6) 
Hawaii 10,247 3 (0.0) 1 (33.3) 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 
Idaho 3,582 2 (0.1) 1 (50.0) 0 1 0 (0.0) (0.0) (0.0) 0 1 0 (0.0) (0.0) (0.0) 
Illinois                  
   Chicago 68,900 178 (0.3) 51 (28.7) 28 11 88 (69.3) (22.0) (71.8) 28 2 97 (76.4) (22.0) (93.3) 
   Illinois (excludes Chicago) 7,147 10 (0.1) 0 (0.0) 8 1 1 (10.0) (80.0) (88.9) 8 1 1 (10.0) (80.0) (88.9) 
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CDC funded jurisdiction 
HIV 
testing 
events 
Previous 
HIV positive 
testing 
events 
Already 
in HIV 
medical 
care Linkage to HIV Medical Care* Linkage to HIV Medical Care in 90 days* 
No. No. 
(Positiv
e %) No. 
(% in 
care) Linked 
Not 
linked Missing/invalid (Missing/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Indiana 13,960 7 (0.1) 0 (0.0) 5 1 1 (14.3) (71.4) (83.3) 3 3 1 (14.3) (42.9) (50.0) 
Iowa 5,100 1 (0.0) 0 (0.0) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
Kansas 19,698 3 (0.0) 3 (100.0
) 
0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Kentucky 26,535 18 (0.1) 1 (5.6) 6 4 7 (41.2) (35.3) (60.0) 6 1 10 (58.8) (35.3) (85.7) 
Louisiana 94,891 82 (0.1) 0 (0.0) 68 14 0 (0.0) (82.9) (82.9) 63 9 10 (12.2) (76.8) (87.5) 
Maine 2,838 6 (0.2) 0 (0.0) 6 0 0 (0.0) (100.0) (100.0) 4 2 0 (0.0) (66.7) (66.7) 
Maryland                  
   Baltimore 48,440 87 (0.2) 25 (28.7) 34 18 10 (16.1) (54.8) (65.4) 34 14 14 (22.6) (54.8) (70.8) 
   Maryland (excludes Baltimore) 46,572 123 (0.3) 25 (20.3) 72 23 3 (3.1) (73.5) (75.8) 65 18 15 (15.3) (66.3) (78.3) 
Massachusetts 65,492 259 (0.4) 18 (6.9) 136 105 0 (0.0) (56.4) (56.4) 133 8 100 (41.5) (55.2) (94.3) 
Michigan 72,860 97 (0.1) 0 (0.0) 0 0 97 (100.0) (0.0) (0.0) 0 0 97 (100.0) (0.0) (0.0) 
Minnesota 13,180 16 (0.1) 1 (6.3) 9 4 2 (13.3) (60.0) (69.2) 9 0 6 (40.0) (60.0) (100.0) 
Mississippi 91,854 260 (0.3) 4 (1.5) 80 117 59 (23.0) (31.3) (40.6) 79 39 138 (53.9) (30.9) (66.9) 
Missouri 85,650 56 (0.1) 8 (14.3) 46 2 0 (0.0) (95.8) (95.8) 42 6 0 (0.0) (87.5) (87.5) 
Montana 2,237 1 (0.0) 0 (0.0) 0 1 0 (0.0) (0.0) (0.0) 0 0 1 (100.0) (0.0) (0.0) 
Nebraska 9,157 5 (0.1) 2 (40.0) 3 0 0 (0.0) (100.0) (100.0) 3 0 0 (0.0) (100.0) (100.0) 
Nevada 23,477 48 (0.2) 5 (10.4) 30 13 0 (0.0) (69.8) (69.8) 30 9 4 (9.3) (69.8) (76.9) 
New Hampshire 903 1 (0.1) 0 (0.0) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
New Jersey 46,282 178 (0.4) 4 (2.2) 157 15 2 (1.1) (90.2) (91.3) 157 10 7 (4.0) (90.2) (94.0) 
New Mexico 11,117 8 (0.1) 2 (25.0) 3 3 0 (0.0) (50.0) (50.0) 3 1 2 (33.3) (50.0) (75.0) 
New York                  
   New York City 125,711 155 (0.1) 38 (24.5) 59 18 40 (34.2) (50.4) (76.6) 56 10 51 (43.6) (47.9) (84.8) 
   New York (excludes New York City) 136,063 313 (0.2) 0 (0.0) 288 1 24 (7.7) (92.0) (99.7) 214 27 72 (23.0) (68.4) (88.8) 
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CDC funded jurisdiction 
HIV 
testing 
events 
Previous 
HIV positive 
testing 
events 
Already 
in HIV 
medical 
care Linkage to HIV Medical Care* Linkage to HIV Medical Care in 90 days* 
No. No. 
(Positiv
e %) No. 
(% in 
care) Linked 
Not 
linked Missing/invalid (Missing/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
North Carolina 210,364 213 (0.1) 0 (0.0) 1 0 212 (99.5) (0.5) (100.0) 1 0 212 (99.5) (0.5) (100.0) 
North Dakota 4,134 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Ohio 60,479 54 (0.1) 4 (7.4) 23 3 24 (48.0) (46.0) (88.5) 22 2 26 (52.0) (44.0) (91.7) 
Oklahoma 20,767 49 (0.2) 2 (4.1) 9 18 20 (42.6) (19.1) (33.3) 8 0 39 (83.0) (17.0) (100.0) 
Oregon 11,774 5 (0.0) 0 (0.0) 4 1 0 (0.0) (80.0) (80.0) 4 1 0 (0.0) (80.0) (80.0) 
Pennsylvania                  
   Pennsylvania (excludes Philadelphia) 69,411 38 (0.1) 1 (2.6) 19 12 6 (16.2) (51.4) (61.3) 18 0 19 (51.4) (48.6) (100.0) 
   Philadelphia 93,181 136 (0.1) 20 (14.7) 69 30 17 (14.7) (59.5) (69.7) 64 17 35 (30.2) (55.2) (79.0) 
Rhode Island 4,180 6 (0.1) 0 (0.0) 5 0 1 (16.7) (83.3) (100.0) 5 0 1 (16.7) (83.3) (100.0) 
South Carolina 72,857 82 (0.1) 11 (13.4) 52 12 7 (9.9) (73.2) (81.3) 46 6 19 (26.8) (64.8) (88.5) 
South Dakota 1,400 5 (0.4) 0 (0.0) 1 3 1 (20.0) (20.0) (25.0) 1 0 4 (80.0) (20.0) (100.0) 
Tennessee 140,150 291 (0.2) 25 (8.6) 63 29 174 (65.4) (23.7) (68.5) 17 12 237 (89.1) (6.4) (58.6) 
Texas                  
   Houston 67,212 796 (1.2) 29 (3.6) 220 41 506 (66.0) (28.7) (84.3) 165 55 547 (71.3) (21.5) (75.0) 
   Texas (excludes Houston) 195,330 1,402 (0.7) 0 (0.0) 1,089 146 167 (11.9) (77.7) (88.2) 9 1 1,392 (99.3) (0.6) (90.0) 
Utah 9,007 7 (0.1) 1 (14.3) 4 2 0 (0.0) (66.7) (66.7) 4 0 2 (33.3) (66.7) (100.0) 
Vermont 898 1 (0.1) 0 (0.0) 0 1 0 (0.0) (0.0) (0.0) 0 0 1 (100.0) (0.0) (0.0) 
Virginia 73,196 36 (0.0) 5 (13.9) 24 3 4 (12.9) (77.4) (88.9) 23 2 6 (19.4) (74.2) (92.0) 
Washington 14,292 74 (0.5) 5 (6.8) 61 7 1 (1.4) (88.4) (89.7) 61 4 4 (5.8) (88.4) (93.8) 
West Virginia 1,768 1 (0.1) 0 (0.0) 0 0 1 (100.0) (0.0) (0.0) 0 0 1 (100.0) (0.0) (0.0) 
Wisconsin 13,539 24 (0.2) 0 (0.0) 12 3 9 (37.5) (50.0) (80.0) 12 1 11 (45.8) (50.0) (92.3) 
Wyoming 5,027 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Puerto Rico 35,289 80 (0.2) 26 (32.5) 42 6 6 (11.1) (77.8) (87.5) 41 1 12 (22.2) (75.9) (97.6) 
U.S. Virgin Islands 5,181 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
43 
 
 
 
CDC funded jurisdiction 
HIV 
testing 
events 
Previous 
HIV positive 
testing 
events 
Already 
in HIV 
medical 
care Linkage to HIV Medical Care* Linkage to HIV Medical Care in 90 days* 
No. No. 
(Positiv
e %) No. 
(% in 
care) Linked 
Not 
linked Missing/invalid (Missing/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/Invalid%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Total 3,343,633 8,561 (0.3) 401 (4.7) 5,144 1,035 1,981 (24.3) (63.0) (83.2) 3,670 544 3,946 (48.4) (45.0) (87.1) 
* Persons who reported already being in HIV medical care were excluded from the denominator for both linkage indicators.  
 
 
Table 4: HIV testing and care continuum, including HIV positivity and linkage to care, for newly identified HIV-positive 
persons from 61 health department jurisdictions providing test-level data in the United States, Puerto Rico, and the 
U.S. Virgin Islands, 2013 
CDC funded jurisdiction 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing/inva
lid 
(Missing/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Alabama 94,968 448 (0.5) 170 8 270 (60.3) (37.9) (95.5) 70 6 372 (83.0) (15.6) (92.1) 
Alaska 2,244 5 (0.2) 5 0 0 (0.0) (100.0) (100.0) 5 0 0 (0.0) (100.0) (100.0) 
Arizona 38,802 279 (0.7) 198 75 6 (2.2) (71.0) (72.5) 138 38 103 (36.9) (49.5) (78.4) 
Arkansas 32,087 330 (1.0) 10 154 166 (50.3) (3.0) (6.1) 10 0 320 (97.0) (3.0) (100.0) 
California                
   Los Angeles 125,080 1,040 (0.8) 704 54 282 (27.1) (67.7) (92.9) 614 17 409 (39.3) (59.0) (97.3) 
   San Francisco 36,239 79 (0.2) 56 22 1 (1.3) (70.9) (71.8) 54 3 22 (27.8) (68.4) (94.7) 
   California (excludes Los Angeles and San 
Francisco) 
118,712 509 (0.4) 350 157 2 (0.4) (68.8) (69.0) 315 48 146 (28.7) (61.9) (86.8) 
Colorado 23,171 87 (0.4) 81 6 0 (0.0) (93.1) (93.1) 80 3 4 (4.6) (92.0) (96.4) 
Connecticut 51,658 129 (0.2) 109 12 8 (6.2) (84.5) (90.1) 109 4 16 (12.4) (84.5) (96.5) 
Delaware 11,290 41 (0.4) 30 7 4 (9.8) (73.2) (81.1) 29 4 8 (19.5) (70.7) (87.9) 
District of Columbia 123,707 479 (0.4) 284 120 75 (15.7) (59.3) (70.3) 208 95 176 (36.7) (43.4) (68.6) 
Florida 425,689 2,531 (0.6) 2,028 0 503 (19.9) (80.1) (100.0) 2,028 0 503 (19.9) (80.1) (100.0) 
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CDC funded jurisdiction 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing/inva
lid 
(Missing/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Georgia                
   Atlanta 37,123 627 (1.7) 275 315 37 (5.9) (43.9) (46.6) 257 150 220 (35.1) (41.0) (63.1) 
   Georgia (excludes Atlanta) 81,534 309 (0.4) 139 67 103 (33.3) (45.0) (67.5) 110 32 167 (54.0) (35.6) (77.5) 
Hawaii 10,247 31 (0.3) 26 1 4 (12.9) (83.9) (96.3) 25 1 5 (16.1) (80.6) (96.2) 
Idaho 3,582 5 (0.1) 5 0 0 (0.0) (100.0) (100.0) 5 0 0 (0.0) (100.0) (100.0) 
Illinois                
   Chicago 68,900 313 (0.5) 147 47 119 (38.0) (47.0) (75.8) 147 6 160 (51.1) (47.0) (96.1) 
   Illinois (excludes Chicago) 7,147 80 (1.1) 49 15 16 (20.0) (61.3) (76.6) 43 12 25 (31.3) (53.8) (78.2) 
Indiana 13,960 89 (0.6) 62 11 16 (18.0) (69.7) (84.9) 39 44 6 (6.7) (43.8) (47.0) 
Iowa 5,100 31 (0.6) 21 3 7 (22.6) (67.7) (87.5) 19 4 8 (25.8) (61.3) (82.6) 
Kansas 19,698 43 (0.2) 29 8 6 (14.0) (67.4) (78.4) 29 2 12 (27.9) (67.4) (93.5) 
Kentucky 26,535 124 (0.5) 23 67 34 (27.4) (18.5) (25.6) 23 1 100 (80.6) (18.5) (95.8) 
Louisiana 94,891 318 (0.3) 209 105 4 (1.3) (65.7) (66.6) 190 67 61 (19.2) (59.7) (73.9) 
Maine 2,838 7 (0.2) 7 0 0 (0.0) (100.0) (100.0) 7 0 0 (0.0) (100.0) (100.0) 
Maryland                
   Baltimore 48,440 428 (0.9) 193 229 6 (1.4) (45.1) (45.7) 183 172 73 (17.1) (42.8) (51.5) 
   Maryland (excludes Baltimore) 46,572 225 (0.5) 114 109 2 (0.9) (50.7) (51.1) 110 63 52 (23.1) (48.9) (63.6) 
Massachusetts 65,492 101 (0.2) 56 44 1 (1.0) (55.4) (56.0) 56 4 41 (40.6) (55.4) (93.3) 
Michigan 72,860 385 (0.5) 0 1 384 (99.7) (0.0) (0.0) 0 1 384 (99.7) (0.0) (0.0) 
Minnesota 13,180 91 (0.7) 51 28 12 (13.2) (56.0) (64.6) 50 2 39 (42.9) (54.9) (96.2) 
Mississippi 91,854 1,128 (1.2) 811 85 232 (20.6) (71.9) (90.5) 804 84 240 (21.3) (71.3) (90.5) 
Missouri 85,650 183 (0.2) 140 37 6 (3.3) (76.5) (79.1) 135 22 26 (14.2) (73.8) (86.0) 
Montana 2,237 6 (0.3) 4 2 0 (0.0) (66.7) (66.7) 4 0 2 (33.3) (66.7) (100.0) 
Nebraska 9,157 27 (0.3) 20 6 1 (3.7) (74.1) (76.9) 20 3 4 (14.8) (74.1) (87.0) 
Nevada 23,477 208 (0.9) 171 36 1 (0.5) (82.2) (82.6) 167 22 19 (9.1) (80.3) (88.4) 
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CDC funded jurisdiction 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing/inva
lid 
(Missing/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
New Hampshire 903 3 (0.3) 3 0 0 (0.0) (100.0) (100.0) 3 0 0 (0.0) (100.0) (100.0) 
New Jersey 46,282 305 (0.7) 232 71 2 (0.7) (76.1) (76.6) 232 21 52 (17.0) (76.1) (91.7) 
New Mexico 11,117 59 (0.5) 45 14 0 (0.0) (76.3) (76.3) 44 5 10 (16.9) (74.6) (89.8) 
New York                
   New York City 125,711 722 (0.6) 389 70 263 (36.4) (53.9) (84.7) 368 49 305 (42.2) (51.0) (88.2) 
   New York (excludes New York City) 136,063 563 (0.4) 500 6 57 (10.1) (88.8) (98.8) 410 70 83 (14.7) (72.8) (85.4) 
North Carolina 210,364 504 (0.2) 5 0 499 (99.0) (1.0) (100.0) 5 0 499 (99.0) (1.0) (100.0) 
North Dakota 4,134 5 (0.1) 3 0 2 (40.0) (60.0) (100.0) 3 0 2 (40.0) (60.0) (100.0) 
Ohio 60,479 309 (0.5) 182 27 100 (32.4) (58.9) (87.1) 155 13 141 (45.6) (50.2) (92.3) 
Oklahoma 20,767 116 (0.6) 31 41 44 (37.9) (26.7) (43.1) 28 5 83 (71.6) (24.1) (84.8) 
Oregon 11,774 72 (0.6) 51 19 2 (2.8) (70.8) (72.9) 48 17 7 (9.7) (66.7) (73.8) 
Pennsylvania                
   Pennsylvania (excludes Philadelphia) 69,411 276 (0.4) 185 75 16 (5.8) (67.0) (71.2) 76 2 198 (71.7) (27.5) (97.4) 
   Philadelphia 93,181 428 (0.5) 226 131 71 (16.6) (52.8) (63.3) 215 51 162 (37.9) (50.2) (80.8) 
Rhode Island 4,180 24 (0.6) 22 2 0 (0.0) (91.7) (91.7) 21 1 2 (8.3) (87.5) (95.5) 
South Carolina 72,857 203 (0.3) 126 54 23 (11.3) (62.1) (70.0) 118 25 60 (29.6) (58.1) (82.5) 
South Dakota 1,400 6 (0.4) 4 2 0 (0.0) (66.7) (66.7) 4 0 2 (33.3) (66.7) (100.0) 
Tennessee 140,150 788 (0.6) 161 233 394 (50.0) (20.4) (40.9) 21 113 654 (83.0) (2.7) (15.7) 
Texas                
   Houston 67,212 111 (0.2) 51 52 8 (7.2) (45.9) (49.5) 39 12 60 (54.1) (35.1) (76.5) 
   Texas (excludes Houston) 195,330 1,318 (0.7) 823 215 280 (21.2) (62.4) (79.3) 16 2 1,300 (98.6) (1.2) (88.9) 
Utah 9,007 45 (0.5) 39 6 0 (0.0) (86.7) (86.7) 38 2 5 (11.1) (84.4) (95.0) 
Vermont 898 4 (0.4) 3 1 0 (0.0) (75.0) (75.0) 3 0 1 (25.0) (75.0) (100.0) 
Virginia 73,196 283 (0.4) 177 65 41 (14.5) (62.5) (73.1) 174 18 91 (32.2) (61.5) (90.6) 
Washington 14,292 127 (0.9) 98 16 13 (10.2) (77.2) (86.0) 97 9 21 (16.5) (76.4) (91.5) 
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CDC funded jurisdiction 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing/inva
lid 
(Missing/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked Missing/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
West Virginia 1,768 3 (0.2) 0 1 2 (66.7) (0.0) (0.0) 0 0 3 (100.0) (0.0) (0.0) 
Wisconsin 13,539 97 (0.7) 71 14 12 (12.4) (73.2) (83.5) 71 7 19 (19.6) (73.2) (91.0) 
Wyoming 5,027 6 (0.1) 5 0 1 (16.7) (83.3) (100.0) 5 0 1 (16.7) (83.3) (100.0) 
Puerto Rico 35,289 328 (0.9) 273 40 15 (4.6) (83.2) (87.2) 271 7 50 (15.2) (82.6) (97.5) 
U.S. Virgin Islands 5,181 5 (0.1) 4 0 1 (20.0) (80.0) (100.0) 4 0 1 (20.0) (80.0) (100.0) 
Total 3,343,633 17,426 (0.5) 10,286 2,986 4,154 (23.8) (59.0) (77.5) 8,552 1,339 7,535 (43.2) (49.1) (86.5) 
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Table 5: HIV testing and care continuum, including partner and HIV prevention services, for newly identified HIV-positive 
persons from 61 health department jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin 
Islands, 2013 
Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Alabama 73 14 361 (80.6) (16.3) (83.9) 71 16 361 (80.6) (15.8) (81.6) 162 0 286 (63.8) (36.2) (100.0) 
Alaska 5 0 0 (0.0) (100.0) (100.0) 5 0 0 (0.0) (100.0) (100.0) 5 0 0 (0.0) (100.0) (100.0) 
Arizona 242 31 6 (2.2) (86.7) (88.6) 222 34 23 (8.2) (79.6) (86.7) 240 33 6 (2.2) (86.0) (87.9) 
Arkansas 173 153 4 (1.2) (52.4) (53.1) 12 153 165 (50.0) (3.6) (7.3) 21 151 158 (47.9) (6.4) (12.2) 
California                   
   Los Angeles 755 241 44 (4.2) (72.6) (75.8) 731 265 44 (4.2) (70.3) (73.4) 438 201 401 (38.6) (42.1) (68.5) 
   San Francisco 74 4 1 (1.3) (93.7) (94.9) 56 17 6 (7.6) (70.9) (76.7) 72 7 0 (0.0) (91.1) (91.1) 
   California (excludes Los Angeles and San 
Francisco) 
463 46 0 (0.0) (91.0) (91.0) 67 442 0 (0.0) (13.2) (13.2) 448 61 0 (0.0) (88.0) (88.0) 
Colorado 84 3 0 (0.0) (96.6) (96.6) 80 7 0 (0.0) (92.0) (92.0) 84 3 0 (0.0) (96.6) (96.6) 
Connecticut 113 14 2 (1.6) (87.6) (89.0) 98 16 15 (11.6) (76.0) (86.0) 79 42 8 (6.2) (61.2) (65.3) 
Delaware 33 7 1 (2.4) (80.5) (82.5) 30 8 3 (7.3) (73.2) (78.9) 8 32 1 (2.4) (19.5) (20.0) 
District of Columbia 239 237 3 (0.6) (49.9) (50.2) 147 310 22 (4.6) (30.7) (32.2) 357 119 3 (0.6) (74.5) (75.0) 
Florida 2,423 92 16 (0.6) (95.7) (96.3) 2,423 108 0 (0.0) (95.7) (95.7) 1,723 786 22 (0.9) (68.1) (68.7) 
Georgia                   
   Atlanta 417 194 16 (2.6) (66.5) (68.2) 293 234 100 (15.9) (46.7) (55.6) 515 93 19 (3.0) (82.1) (84.7) 
   Georgia (excludes Atlanta) 258 41 10 (3.2) (83.5) (86.3) 184 55 70 (22.7) (59.5) (77.0) 254 45 10 (3.2) (82.2) (84.9) 
Hawaii 30 0 1 (3.2) (96.8) (100.0) 27 3 1 (3.2) (87.1) (90.0) 29 2 0 (0.0) (93.5) (93.5) 
Idaho 5 0 0 (0.0) (100.0) (100.0) 5 0 0 (0.0) (100.0) (100.0) 5 0 0 (0.0) (100.0) (100.0) 
Illinois                   
   Chicago 173 34 106 (33.9) (55.3) (83.6) 91 48 174 (55.6) (29.1) (65.5) 189 27 97 (31.0) (60.4) (87.5) 
   Illinois (excludes Chicago) 74 6 0 (0.0) (92.5) (92.5) 55 25 0 (0.0) (68.8) (68.8) 50 30 0 (0.0) (62.5) (62.5) 
Indiana 85 1 3 (3.4) (95.5) (98.8) 0 1 88 (98.9) (0.0) (0.0) 33 53 3 (3.4) (37.1) (38.4) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Iowa 22 2 7 (22.6) (71.0) (91.7) 22 2 7 (22.6) (71.0) (91.7) 23 1 7 (22.6) (74.2) (95.8) 
Kansas 42 1 0 (0.0) (97.7) (97.7) 40 3 0 (0.0) (93.0) (93.0) 36 7 0 (0.0) (83.7) (83.7) 
Kentucky 96 18 10 (8.1) (77.4) (84.2) 79 20 25 (20.2) (63.7) (79.8) 90 28 6 (4.8) (72.6) (76.3) 
Louisiana 248 2 68 (21.4) (78.0) (99.2) 63 4 251 (78.9) (19.8) (94.0) 0 2 316 (99.4) (0.0) (0.0) 
Maine 7 0 0 (0.0) (100.0) (100.0) 7 0 0 (0.0) (100.0) (100.0) 4 3 0 (0.0) (57.1) (57.1) 
Maryland                   
   Baltimore 204 207 17 (4.0) (47.7) (49.6) 148 263 17 (4.0) (34.6) (36.0) 55 0 373 (87.1) (12.9) (100.0) 
   Maryland (excludes Baltimore) 201 22 2 (0.9) (89.3) (90.1) 153 69 3 (1.3) (68.0) (68.9) 53 0 172 (76.4) (23.6) (100.0) 
Massachusetts 51 26 24 (23.8) (50.5) (66.2) 32 32 37 (36.6) (31.7) (50.0) 57 18 26 (25.7) (56.4) (76.0) 
Michigan 166 0 219 (56.9) (43.1) (100.0) 98 35 252 (65.5) (25.5) (73.7) 65 1 319 (82.9) (16.9) (98.5) 
Minnesota 78 6 7 (7.7) (85.7) (92.9) 54 8 29 (31.9) (59.3) (87.1) 77 5 9 (9.9) (84.6) (93.9) 
Mississippi 729 14 385 (34.1) (64.6) (98.1) 649 39 440 (39.0) (57.5) (94.3) 871 16 241 (21.4) (77.2) (98.2) 
Missouri 161 19 3 (1.6) (88.0) (89.4) 138 34 11 (6.0) (75.4) (80.2) 159 20 4 (2.2) (86.9) (88.8) 
Montana 6 0 0 (0.0) (100.0) (100.0) 6 0 0 (0.0) (100.0) (100.0) 6 0 0 (0.0) (100.0) (100.0) 
Nebraska 25 2 0 (0.0) (92.6) (92.6) 21 6 0 (0.0) (77.8) (77.8) 24 3 0 (0.0) (88.9) (88.9) 
Nevada 192 16 0 (0.0) (92.3) (92.3) 180 18 10 (4.8) (86.5) (90.9) 188 20 0 (0.0) (90.4) (90.4) 
New Hampshire 3 0 0 (0.0) (100.0) (100.0) 3 0 0 (0.0) (100.0) (100.0) 3 0 0 (0.0) (100.0) (100.0) 
New Jersey 286 18 1 (0.3) (93.8) (94.1) 282 18 5 (1.6) (92.5) (94.0) 217 84 4 (1.3) (71.1) (72.1) 
New Mexico 50 9 0 (0.0) (84.7) (84.7) 44 15 0 (0.0) (74.6) (74.6) 45 14 0 (0.0) (76.3) (76.3) 
New York                   
   New York City 486 29 207 (28.7) (67.3) (94.4) 430 70 222 (30.7) (59.6) (86.0) 485 88 149 (20.6) (67.2) (84.6) 
   New York (excludes New York City) 470 43 50 (8.9) (83.5) (91.6) 318 53 192 (34.1) (56.5) (85.7) 487 27 49 (8.7) (86.5) (94.7) 
North Carolina 492 0 12 (2.4) (97.6) (100.0) 6 0 498 (98.8) (1.2) (100.0) 6 0 498 (98.8) (1.2) (100.0) 
North Dakota 3 0 2 (40.0) (60.0) (100.0) 3 2 0 (0.0) (60.0) (60.0) 3 0 2 (40.0) (60.0) (100.0) 
Ohio 267 19 23 (7.4) (86.4) (93.4) 196 30 83 (26.9) (63.4) (86.7) 261 25 23 (7.4) (84.5) (91.3) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Oklahoma 66 6 44 (37.9) (56.9) (91.7) 35 9 72 (62.1) (30.2) (79.5) 59 13 44 (37.9) (50.9) (81.9) 
Oregon 54 10 8 (11.1) (75.0) (84.4) 51 19 2 (2.8) (70.8) (72.9) 0 71 1 (1.4) (0.0) (0.0) 
Pennsylvania                   
   Pennsylvania (excludes Philadelphia) 106 167 3 (1.1) (38.4) (38.8) 82 175 19 (6.9) (29.7) (31.9) 221 47 8 (2.9) (80.1) (82.5) 
   Philadelphia 279 149 0 (0.0) (65.2) (65.2) 94 221 113 (26.4) (22.0) (29.8) 329 71 28 (6.5) (76.9) (82.3) 
Rhode Island 17 7 0 (0.0) (70.8) (70.8) 17 7 0 (0.0) (70.8) (70.8) 24 0 0 (0.0) (100.0) (100.0) 
South Carolina 155 29 19 (9.4) (76.4) (84.2) 116 37 50 (24.6) (57.1) (75.8) 92 67 44 (21.7) (45.3) (57.9) 
South Dakota 4 2 0 (0.0) (66.7) (66.7) 4 2 0 (0.0) (66.7) (66.7) 3 3 0 (0.0) (50.0) (50.0) 
Tennessee 417 34 337 (42.8) (52.9) (92.5) 22 39 727 (92.3) (2.8) (36.1) 403 32 353 (44.8) (51.1) (92.6) 
Texas                   
   Houston 99 4 8 (7.2) (89.2) (96.1) 99 4 8 (7.2) (89.2) (96.1) 99 4 8 (7.2) (89.2) (96.1) 
   Texas (excludes Houston) 61 37 1,220 (92.6) (4.6) (62.2) 51 38 1,229 (93.2) (3.9) (57.3) 45 52 1,221 (92.6) (3.4) (46.4) 
Utah 40 2 3 (6.7) (88.9) (95.2) 38 4 3 (6.7) (84.4) (90.5) 45 0 0 (0.0) (100.0) (100.0) 
Vermont 4 0 0 (0.0) (100.0) (100.0) 3 1 0 (0.0) (75.0) (75.0) 4 0 0 (0.0) (100.0) (100.0) 
Virginia 232 47 4 (1.4) (82.0) (83.2) 195 54 34 (12.0) (68.9) (78.3) 212 65 6 (2.1) (74.9) (76.5) 
Washington 111 15 1 (0.8) (87.4) (88.1) 100 17 10 (7.9) (78.7) (85.5) 37 88 2 (1.6) (29.1) (29.6) 
West Virginia 0 2 1 (33.3) (0.0) (0.0) 0 2 1 (33.3) (0.0) (0.0) 1 1 1 (33.3) (33.3) (50.0) 
Wisconsin 77 8 12 (12.4) (79.4) (90.6) 60 25 12 (12.4) (61.9) (70.6) 42 42 13 (13.4) (43.3) (50.0) 
Wyoming 6 0 0 (0.0) (100.0) (100.0) 5 1 0 (0.0) (83.3) (83.3) 6 0 0 (0.0) (100.0) (100.0) 
Puerto Rico 292 31 5 (1.5) (89.0) (90.4) 260 38 30 (9.1) (79.3) (87.2) 276 46 6 (1.8) (84.1) (85.7) 
U.S. Virgin Islands 4 0 1 (20.0) (80.0) (100.0) 4 0 1 (20.0) (80.0) (100.0) 2 0 3 (60.0) (40.0) (100.0) 
Total 12,028 2,121 3,277 (18.8) (69.0) (85.0) 8,805 3,156 5,465 (31.4) (50.5) (73.6) 9,827 2,649 4,950 (28.4) (56.4) (78.8) 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 6: HIV testing and care continuum of testing events, including HIV positivity and linkage to care, by demographic 
characteristics of newly identified HIV-positive persons from 61 health department jurisdictions providing test-level 
data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positiv
e %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                
   <13 5,537 25 (0.5) 8 10 7 (28.0) (32.0) (44.4) 5 3 17 (68.0) (20.0) (62.5) 
   13-19 279,412 579 (0.2) 309 105 165 (28.5) (53.4) (74.6) 260 38 281 (48.5) (44.9) (87.2) 
   20-29 1,358,687 6,895 (0.5) 4,080 1,152 1,663 (24.1) (59.2) (78.0) 3,387 527 2,981 (43.2) (49.1) (86.5) 
   30-39 756,782 4,118 (0.5) 2,493 676 949 (23.0) (60.5) (78.7) 2,080 268 1,770 (43.0) (50.5) (88.6) 
   40-49 461,696 3,056 (0.7) 1,779 548 729 (23.9) (58.2) (76.5) 1,490 232 1,334 (43.7) (48.8) (86.5) 
   50+ 456,169 2,434 (0.5) 1,416 454 564 (23.2) (58.2) (75.7) 1,160 220 1,054 (43.3) (47.7) (84.1) 
   Missing/Invalid 25,350 319 (1.3) 201 41 77 (24.1) (63.0) (83.1) 170 51 98 (30.7) (53.3) (76.9) 
Gender                
   Male 1,632,645 13,976 (0.9) 8,412 2,405 3,159 (22.6) (60.2) (77.8) 6,952 1,089 5,935 (42.5) (49.7) (86.5) 
   Female 1,687,367 3,188 (0.2) 1,740 538 910 (28.5) (54.6) (76.4) 1,481 232 1,475 (46.3) (46.5) (86.5) 
   Transgender 11,047 209 (1.9) 118 41 51 (24.4) (56.5) (74.2) 103 17 89 (42.6) (49.3) (85.8) 
   Declined/Not asked 6,344 23 (0.4) 14 3 6 (26.1) (60.9) (82.4) 14 1 8 (34.8) (60.9) (93.3) 
   Missing/Invalid 6,230 30 (0.5) 2 0 28 (93.3) (6.7) (100.0) 2 0 28 (93.3) (6.7) (100.0) 
Race/Ethnicity                
   White 901,973 3,445 (0.4) 2,160 535 750 (21.8) (62.7) (80.1) 1,775 193 1,477 (42.9) (51.5) (90.2) 
   Black or African American 1,506,016 9,571 (0.6) 5,121 1,819 2,631 (27.5) (53.5) (73.8) 4,261 904 4,406 (46.0) (44.5) (82.5) 
   Hispanic or Latino 713,058 3,407 (0.5) 2,424 432 551 (16.2) (71.1) (84.9) 2,005 166 1,236 (36.3) (58.8) (92.4) 
   Asian 66,997 243 (0.4) 155 38 50 (20.6) (63.8) (80.3) 131 21 91 (37.4) (53.9) (86.2) 
   American Indian or Alaska Native 16,587 55 (0.3) 25 10 20 (36.4) (45.5) (71.4) 25 3 27 (49.1) (45.5) (89.3) 
   Native Hawaiian or Pacific Islander 8,466 38 (0.4) 23 7 8 (21.1) (60.5) (76.7) 18 4 16 (42.1) (47.4) (81.8) 
   Multi-race 22,758 229 (1.0) 153 38 38 (16.6) (66.8) (80.1) 136 14 79 (34.5) (59.4) (90.7) 
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Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positiv
e %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Declined 16,949 58 (0.3) 35 14 9 (15.5) (60.3) (71.4) 33 6 19 (32.8) (56.9) (84.6) 
   Don’t know/Not asked 77,533 298 (0.4) 145 80 73 (24.5) (48.7) (64.4) 123 20 155 (52.0) (41.3) (86.0) 
   Missing/Invalid 13,296 82 (0.6) 45 13 24 (29.3) (54.9) (77.6) 45 8 29 (35.4) (54.9) (84.9) 
Region                
   Northeast 596,617 2,562 (0.4) 1,732 412 418 (16.3) (67.6) (80.8) 1,500 202 860 (33.6) (58.5) (88.1) 
   Midwest 375,204 1,659 (0.4) 779 199 681 (41.0) (47.0) (79.7) 715 116 828 (49.9) (43.1) (86.0) 
   South 1,896,334 10,314 (0.5) 5,660 1,927 2,727 (26.4) (54.9) (74.6) 4,423 849 5,042 (48.9) (42.9) (83.9) 
   West 435,008 2,558 (0.6) 1,838 408 312 (12.2) (71.9) (81.8) 1,639 165 754 (29.5) (64.1) (90.9) 
   U.S. dependent areas 40,470 333 (0.8) 277 40 16 (4.8) (83.2) (87.4) 275 7 51 (15.3) (82.6) (97.5) 
Testing site type                
   Health care facilities including correctional facility clinics 2,298,949 10,144 (0.4) 6,229 1,807 2,108 (20.8) (61.4) (77.5) 5,212 841 4,091 (40.3) (51.4) (86.1) 
   Non-health care facilities 977,645 7,029 (0.7) 4,026 1,157 1,846 (26.3) (57.3) (77.7) 3,323 483 3,223 (45.9) (47.3) (87.3) 
   Missing/Invalid 67,039 253 (0.4) 31 22 200 (79.1) (12.3) (58.5) 17 15 221 (87.4) (6.7) (53.1) 
Target Populationb                
   Male-to-male sexual contact and injection drug use 7,284 320 N/Ac 214 55 51 (15.9) (66.9) (79.6) 186 26 108 (33.8) (58.1) (87.7) 
   Male-to-male sexual contact 245,467 7,576 N/Ac  5,028 1,242 1,306 (17.2) (66.4) (80.2) 4,601 607 2,368 (31.3) (60.7) (88.3) 
   Transgender and injection drug use 545 9 N/Ac  4 2 3 (33.3) (44.4) (66.7) 3 1 5 (55.6) (33.3) (75.0) 
   Transgender 10,502 200 N/Ac  114 38 48 (24.0) (57.0) (75.0) 100 16 84 (42.0) (50.0) (86.2) 
   Injection drug use 82,919 347 N/Ac  188 73 86 (24.8) (54.2) (72.0) 163 32 152 (43.8) (47.0) (83.6) 
   Heterosexual males 571,333 2,505 N/Ac  1,360 498 647 (25.8) (54.3) (73.2) 1,219 299 987 (39.4) (48.7) (80.3) 
   Heterosexual females 829,779 2,147 N/Ac  1,250 353 544 (25.3) (58.2) (78.0) 1,162 176 809 (37.7) (54.1) (86.8) 
   Not asked/No risk/Missing/Invalid 1,595,804 4,322 N/Ac  2,128 725 1,469 (34.0) (49.2) (74.6) 1,118 182 3,022 (69.9) (25.9) (86.0) 
Rapid test used in testing event                
   Yes 1,956,524 11,528 (0.6) 7,184 1,978 2,366 (20.5) (62.3) (78.4) 6,239 884 4,405 (38.2) (54.1) (87.6) 
   No 1,385,231 5,892 (0.4) 3,102 1,007 1,783 (30.3) (52.6) (75.5) 2,313 455 3,124 (53.0) (39.3) (83.6) 
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Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positiv
e %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Missing/Invalid 1,878 6 (0.3) 0 1 5 (83.3) (0.0) (0.0) 0 0 6 (100.0) (0.0) (0.0) 
Total 3,343,633 17,426 (0.5) 10,286 2,986 4,154 (23.8) (59.0) (77.5) 8,552 1,339 7,535 (43.2) (49.1) (86.5) 
a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2013, data for 4.2% of newly identified HIV-positive individuals in 2013  
were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data. 
b Data to identify target populations are not required for persons who test HIV-negative in health care facilities. 
c N/A: Data to identify target populations are required for all testing events conducted in non-health care facilities but are only required for HIV-positive individuals from health care facilities; therefore the denominator is unknown and we are 
unable to calculate “New positive %”. 
Table 7: HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of 
newly identified HIV-positive persons from 61 health department jurisdictions providing test-level data in the United States, 
Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                   
   <13 12 11 2 (8.0) (48.0) (52.2) 8 13 4 (16.0) (32.0) (38.1) 15 7 3 (12.0) (60.0) (68.2) 
   13-19 412 57 110 (19.0) (71.2) (87.8) 272 82 225 (38.9) (47.0) (76.8) 315 83 181 (31.3) (54.4) (79.1) 
   20-29 4,922 742 1,231 (17.9) (71.4) (86.9) 3,493 1,146 2,256 (32.7) (50.7) (75.3) 4,028 1,018 1,849 (26.8) (58.4) (79.8) 
   30-39 2,845 453 820 (19.9) (69.1) (86.3) 2,117 713 1,288 (31.3) (51.4) (74.8) 2,278 664 1,176 (28.6) (55.3) (77.4) 
   40-49 2,017 442 597 (19.5) (66.0) (82.0) 1,514 638 904 (29.6) (49.5) (70.4) 1,614 516 926 (30.3) (52.8) (75.8) 
   50+ 1,565 392 477 (19.6) (64.3) (80.0) 1,186 527 721 (29.6) (48.7) (69.2) 1,319 340 775 (31.8) (54.2) (79.5) 
   Missing/Invalid 255 24 40 (12.5) (79.9) (91.4) 215 37 67 (21.0) (67.4) (85.3) 258 21 40 (12.5) (80.9) (92.5) 
Gender                   
   Male 9,714 1,683 2,579 (18.5) (69.5) (85.2) 7,120 2,560 4,296 (30.7) (50.9) (73.6) 8,032 2,108 3,836 (27.4) (57.5) (79.2) 
   Female 2,118 402 668 (21.0) (66.4) (84.0) 1,563 549 1,076 (33.8) (49.0) (74.0) 1,669 490 1,029 (32.3) (52.4) (77.3) 
  Transgender 148 33 28 (13.4) (70.8) (81.8) 103 43 63 (30.1) (49.2) (70.5) 111 44 54 (25.8) (53.1) (71.6) 
   Declined/Not asked 18 3 2 (8.7) (78.3) (85.7) 17 4 2 (8.7) (73.9) (81.0) 15 6 2 (8.7) (65.2) (71.4) 
   Missing/Invalid 30 0 0 (0.0) (100.0) (100.0) 2 0 28 (93.3) (6.7) (100.0) 0 1 29 (96.7) (0.0) (0.0) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Race/Ethnicity                   
   White 2,498 383 564 (16.4) (72.5) (86.7) 1,806 628 1,011 (29.3) (52.4) (74.2) 2,009 577 859 (24.9) (58.3) (77.7) 
   Black or African American 6,298 1,230 2,043 (21.3) (65.8) (83.7) 4,441 1,682 3,448 (36.0) (46.4) (72.5) 5,126 1,308 3,137 (32.8) (53.6) (79.7) 
   Hispanic or Latino 2,513 346 548 (16.1) (73.8) (87.9) 2,049 598 760 (22.3) (60.1) (77.4) 2,077 589 741 (21.7) (61.0) (77.9) 
   Asian 185 30 28 (11.5) (76.1) (86.0) 134 60 49 (20.2) (55.1) (69.1) 156 33 54 (22.2) (64.2) (82.5) 
   American Indian or Alaska Native 42 4 9 (16.4) (76.4) (91.3) 26 6 23 (41.8) (47.3) (81.3) 27 5 23 (41.8) (49.1) (84.4) 
   Native Hawaiian or Pacific Islander 27 9 2 (5.3) (71.1) (75.0) 19 15 4 (10.5) (50.0) (55.9) 20 10 8 (21.1) (52.6) (66.7) 
   Multi-race 190 19 20 (8.7) (83.0) (90.9) 140 37 52 (22.7) (61.1) (79.1) 165 38 26 (11.4) (72.1) (81.3) 
   Declined 42 14 2 (3.4) (72.4) (75.0) 35 20 3 (5.2) (60.3) (63.6) 36 13 9 (15.5) (62.1) (73.5) 
   Don’t know/Not asked 158 85 55 (18.5) (53.0) (65.0) 103 107 88 (29.5) (34.6) (49.0) 155 74 69 (23.2) (52.0) (67.7) 
   Missing/Invalid 75 1 6 (7.3) (91.5) (98.7) 52 3 27 (32.9) (63.4) (94.5) 56 2 24 (29.3) (68.3) (96.6) 
Region                   
   Northeast 1,822 453 287 (11.2) (71.1) (80.1) 1,366 593 603 (23.5) (53.3) (69.7) 1,910 380 272 (10.6) (74.6) (83.4) 
   Midwest 1,177 100 382 (23.0) (70.9) (92.2) 782 221 656 (39.5) (47.1) (78.0) 965 217 477 (28.8) (58.2) (81.6) 
   South 6,616 1,160 2,538 (24.6) (64.1) (85.1) 4,776 1,462 4,076 (39.5) (46.3) (76.6) 5,026 1,506 3,782 (36.7) (48.7) (76.9) 
   West 2,117 377 64 (2.5) (82.8) (84.9) 1,617 842 99 (3.9) (63.2) (65.8) 1,648 500 410 (16.0) (64.4) (76.7) 
   U.S. dependent areas 296 31 6 (1.8) (88.9) (90.5) 264 38 31 (9.3) (79.3) (87.4) 278 46 9 (2.7) (83.5) (85.8) 
Testing site type                   
   Health care facilities including correctional 
facility clinics 
6,971 1,182 1,991 (19.6) (68.7) (85.5) 5,306 1,805 3,033 (29.9) (52.3) (74.6) 6,103 1,516 2,525 (24.9) (60.2) (80.1) 
   Non-health care facilities 5,024 914 1,091 (15.5) (71.5) (84.6) 3,488 1,324 2,217 (31.5) (49.6) (72.5) 3,682 1,128 2,219 (31.6) (52.4) (76.5) 
   Missing/Invalid 33 25 195 (77.1) (13.0) (56.9) 11 27 215 (85.0) (4.3) (28.9) 42 5 206 (81.4) (16.6) (89.4) 
Target Populationb                    
   Male-to-male sexual contact and injection 
drug use 
256 30 34 (10.6) (80.0) (89.5) 189 66 65 (20.3) (59.1) (74.1) 206 47 67 (20.9) (64.4) (81.4) 
   Male-to-male sexual contact 6,278 752 546 (7.2) (82.9) (89.3) 4,708 1,353 1,515 (20.0) (62.1) (77.7) 5,253 1,209 1,114 (14.7) (69.3) (81.3) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Transgender and injection drug use 6 1 2 (22.2) (66.7) (85.7) 6 1 2 (22.2) (66.7) (85.7) 3 3 3 (33.3) (33.3) (50.0) 
   Transgender 142 32 26 (13.0) (71.0) (81.6) 97 42 61 (30.5) (48.5) (69.8) 108 41 51 (25.5) (54.0) (72.5) 
   Injection drug use 247 36 64 (18.4) (71.2) (87.3) 175 66 106 (30.5) (50.4) (72.6) 198 52 97 (28.0) (57.1) (79.2) 
   Heterosexual males 1,835 345 325 (13.0) (73.3) (84.2) 1,345 464 696 (27.8) (53.7) (74.4) 1,420 401 684 (27.3) (56.7) (78.0) 
   Heterosexual females 1,645 252 250 (11.6) (76.6) (86.7) 1,229 357 561 (26.1) (57.2) (77.5) 1,284 362 501 (23.3) (59.8) (78.0) 
   Not asked/No risk/Missing/Invalid 1,619 673 2,030 (47.0) (37.5) (70.6) 1,056 807 2,459 (56.9) (24.4) (56.7) 1,355 534 2,433 (56.3) (31.4) (71.7) 
Rapid test used in testing event                   
   Yes 8,492 1,408 1,628 (14.1) (73.7) (85.8) 6,465 2,239 2,824 (24.5) (56.1) (74.3) 6,938 1,959 2,631 (22.8) (60.2) (78.0) 
   No 3,531 713 1,648 (28.0) (59.9) (83.2) 2,340 917 2,635 (44.7) (39.7) (71.8) 2,889 690 2,313 (39.3) (49.0) (80.7) 
   Missing/Invalid 5 0 1 (16.7) (83.3) (100.0) 0 0 6 (100.0) (0.0) (0.0) 0 0 6 (100.0) (0.0) (0.0) 
Total 12,028 2,121 3,277 (18.8) (69.0) (85.0) 8,805 3,156 5,465 (31.4) (50.5) (73.6) 9,827 2,649 4,950 (28.4) (56.4) (78.8) 
a Interviewed for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
b Data to identify target populations are not required for persons who test HIV-negative in health care facilities. 
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Table 8: HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics of 
newly identified HIV-positive persons tested in health care and correctional facilities from 61 health department 
jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                
   <13 3,391 15 (0.4) 5 5 5 (33.3) (33.3) (50.0) 3 2 10 (66.7) (20.0) (60.0) 
   13-19 192,395 337 (0.2) 187 67 83 (24.6) (55.5) (73.6) 154 24 159 (47.2) (45.7) (86.5) 
   20-29 931,897 3,964 (0.4) 2,425 718 821 (20.7) (61.2) (77.2) 2,027 363 1,574 (39.7) (51.1) (84.8) 
   30-39 517,695 2,438 (0.5) 1,500 446 492 (20.2) (61.5) (77.1) 1,273 187 978 (40.1) (52.2) (87.2) 
   40-49 310,179 1,721 (0.6) 1,053 313 355 (20.6) (61.2) (77.1) 882 125 714 (41.5) (51.2) (87.6) 
   50+ 321,025 1,369 (0.4) 861 225 283 (20.7) (62.9) (79.3) 704 94 571 (41.7) (51.4) (88.2) 
   Missing/Invalid 22,367 300 (1.3) 198 33 69 (23.0) (66.0) (85.7) 169 46 85 (28.3) (56.3) (78.6) 
Gender                
   Male 1,038,430 7,976 (0.8) 5,010 1,443 1,523 (19.1) (62.8) (77.6) 4,160 699 3,117 (39.1) (52.2) (85.6) 
   Female 1,246,697 2,036 (0.2) 1,146 348 542 (26.6) (56.3) (76.7) 988 133 915 (44.9) (48.5) (88.1) 
   Transgender 4,955 92 (1.9) 62 14 16 (17.4) (67.4) (81.6) 53 8 31 (33.7) (57.6) (86.9) 
   Declined/Not asked 4,227 16 (0.4) 10 2 4 (25.0) (62.5) (83.3) 10 1 5 (31.3) (62.5) (90.9) 
   Missing/Invalid 4,640 24 (0.5) 1 0 23 (95.8) (4.2) (100.0) 1 0 23 (95.8) (4.2) (100.0) 
Race/Ethnicity                
   White 623,701 2,003 (0.3) 1,258 351 394 (19.7) (62.8) (78.2) 1,024 120 859 (42.9) (51.1) (89.5) 
   Black or African American 1,050,918 5,617 (0.5) 3,147 1,065 1,405 (25.0) (56.0) (74.7) 2,636 554 2,427 (43.2) (46.9) (82.6) 
   Hispanic or Latino 478,689 1,920 (0.4) 1,447 257 216 (11.3) (75.4) (84.9) 1,222 115 583 (30.4) (63.6) (91.4) 
   Asian 44,282 124 (0.3) 86 22 16 (12.9) (69.4) (79.6) 72 12 40 (32.3) (58.1) (85.7) 
   American Indian or Alaska Native 7,688 22 (0.3) 13 4 5 (22.7) (59.1) (76.5) 13 1 8 (36.4) (59.1) (92.9) 
   Native Hawaiian or Pacific Islander 4,655 19 (0.4) 13 3 3 (15.8) (68.4) (81.3) 10 4 5 (26.3) (52.6) (71.4) 
   Multi-race 12,221 127 (1.0) 90 21 16 (12.6) (70.9) (81.1) 79 11 37 (29.1) (62.2) (87.8) 
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Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Declined 13,526 38 (0.3) 25 11 2 (5.3) (65.8) (69.4) 24 5 9 (23.7) (63.2) (82.8) 
   Don’t know/Not asked 59,251 214 (0.4) 108 62 44 (20.6) (50.5) (63.5) 90 12 112 (52.3) (42.1) (88.2) 
   Missing/Invalid 4,018 60 (1.5) 42 11 7 (11.7) (70.0) (79.2) 42 7 11 (18.3) (70.0) (85.7) 
Region                
   Northeast 416,750 1,497 (0.4) 1,158 254 85 (5.7) (77.4) (82.0) 982 137 378 (25.3) (65.6) (87.8) 
   Midwest 280,063 962 (0.3) 433 91 438 (45.5) (45.0) (82.6) 403 42 517 (53.7) (41.9) (90.6) 
   South 1,288,229 5,940 (0.5) 3,267 1,201 1,472 (24.8) (55.0) (73.1) 2,571 557 2,812 (47.3) (43.3) (82.2) 
   West 283,926 1,461 (0.5) 1,121 235 105 (7.2) (76.7) (82.7) 1,007 100 354 (24.2) (68.9) (91.0) 
   U.S. dependent areas 29,981 284 (0.9) 250 26 8 (2.8) (88.0) (90.6) 249 5 30 (10.6) (87.7) (98.0) 
Target Populationb                 
   Male-to-male sexual contact and injection drug use 2,950 169 N/Ac 118 33 18 (10.7) (69.8) (78.1) 108 17 44 (26.0) (63.9) (86.4) 
   Male-to-male sexual contact 95,026 3,962 N/Ac 2,807 670 485 (12.2) (70.8) (80.7) 2,561 406 995 (25.1) (64.6) (86.3) 
   Transgender and injection drug use 192 4 N/Ac 1 2 1 (25.0) (25.0) (33.3) 0 1 3 (75.0) (0.0) (0.0) 
   Transgender 4,763 88 N/Ac 61 12 15 (17.0) (69.3) (83.6) 53 7 28 (31.8) (60.2) (88.3) 
   Injection drug use 42,900 143 N/Ac 82 33 28 (19.6) (57.3) (71.3) 70 15 58 (40.6) (49.0) (82.4) 
   Heterosexual males 335,471 1,478 N/Ac 901 285 292 (19.8) (61.0) (76.0) 809 174 495 (33.5) (54.7) (82.3) 
   Heterosexual females 552,727 1,365 N/Ac 840 215 310 (22.7) (61.5) (79.6) 778 103 484 (35.5) (57.0) (88.3) 
   Not asked/No risk/Missing/Invalid 1,264,920 2,935 N/Ac 1,419 557 959 (32.7) (48.3) (71.8) 833 118 1,984 (67.6) (28.4) (87.6) 
Rapid test used in testing event                
   Yes 1,231,009 5,933 (0.5) 3,866 1,071 996 (16.8) (65.2) (78.3) 3,383 546 2,004 (33.8) (57.0) (86.1) 
   No 1,066,162 4,205 (0.4) 2,363 735 1,107 (26.3) (56.2) (76.3) 1,829 295 2,081 (49.5) (43.5) (86.1) 
   Missing/Invalid 1,778 6 (0.3) 0 1 5 (83.3) (0.0) (0.0) 0 0 6 (100.0) (0.0) .... 
Total 2,298,949 10,144 (0.4) 6,229 1,807 2,108 (20.8) (61.4) (77.5) 5,212 841 4,091 (40.3) (51.4) (86.1) 
a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 7.3% of newly identified HIV-positive individuals  
identified in health care and correctional facilities in 2013 were reported using the previous version of the testing form. These data are represented as missing/invalid data. 
b Data to identify target populations are not required for persons who test HIV-negative in health care facilities. 
c N/A: Data to identify target populations are required for all testing events conducted in non-health care facilities but are only required for HIV-positive individuals from health care facilities; therefore the denominator is unknown and we are 
unable to calculate “New positive %”. 
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Table 9: HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of 
newly identified HIV-positive persons tested in health care and correctional facilities from 61 health department jurisdictions 
providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                   
   <13 6 8 1 (6.7) (40.0) (42.9) 4 8 3 (20.0) (26.7) (33.3) 7 6 2 (13.3) (46.7) (53.8) 
   13-19 240 34 63 (18.7) (71.2) (87.6) 167 48 122 (36.2) (49.6) (77.7) 200 46 91 (27.0) (59.3) (81.3) 
   20-29 2,855 407 702 (17.7) (72.0) (87.5) 2,141 634 1,189 (30.0) (54.0) (77.2) 2,455 570 939 (23.7) (61.9) (81.2) 
   30-39 1,634 287 517 (21.2) (67.0) (85.1) 1,242 445 751 (30.8) (50.9) (73.6) 1,399 417 622 (25.5) (57.4) (77.0) 
   40-49 1,118 243 360 (20.9) (65.0) (82.1) 858 369 494 (28.7) (49.9) (69.9) 978 293 450 (26.1) (56.8) (76.9) 
   50+ 874 185 310 (22.6) (63.8) (82.5) 684 272 413 (30.2) (50.0) (71.5) 815 169 385 (28.1) (59.5) (82.8) 
   Missing/Invalid 244 18 38 (12.7) (81.3) (93.1) 210 29 61 (20.3) (70.0) (87.9) 249 15 36 (12.0) (83.0) (94.3) 
Gender                   
   Male 5,540 912 1,524 (19.1) (69.5) (85.9) 4,251 1,440 2,285 (28.6) (53.3) (74.7) 4,923 1,194 1,859 (23.3) (61.7) (80.5) 
   Female 1,322 256 458 (22.5) (64.9) (83.8) 988 348 700 (34.4) (48.5) (74.0) 1,117 300 619 (30.4) (54.9) (78.8) 
   Transgender 73 12 7 (7.6) (79.3) (85.9) 54 15 23 (25.0) (58.7) (78.3) 53 18 21 (22.8) (57.6) (74.6) 
   Declined/Not asked 12 2 2 (12.5) (75.0) (85.7) 12 2 2 (12.5) (75.0) (85.7) 10 4 2 (12.5) (62.5) (71.4) 
   Missing/Invalid 24 0 0 (0.0) (100.0) (100.0) 1 0 23 (95.8) (4.2) (100.0) 0 0 24 (100.0) (0.0) .... 
Race/Ethnicity                   
   White 1,418 249 336 (16.8) (70.8) (85.1) 1,030 396 577 (28.8) (51.4) (72.2) 1,220 349 434 (21.7) (60.9) (77.8) 
   Black or African American 3,675 616 1,326 (23.6) (65.4) (85.6) 2,750 875 1,992 (35.5) (49.0) (75.9) 3,217 715 1,685 (30.0) (57.3) (81.8) 
   Hispanic or Latino 1,455 204 261 (13.6) (75.8) (87.7) 1,206 366 348 (18.1) (62.8) (76.7) 1,262 334 324 (16.9) (65.7) (79.1) 
   Asian 91 19 14 (11.3) (73.4) (82.7) 71 34 19 (15.3) (57.3) (67.6) 85 20 19 (15.3) (68.5) (81.0) 
   American Indian or Alaska Native 16 2 4 (18.2) (72.7) (88.9) 12 3 7 (31.8) (54.5) (80.0) 15 3 4 (18.2) (68.2) (83.3) 
   Native Hawaiian or Pacific Islander 11 6 2 (10.5) (57.9) (64.7) 7 10 2 (10.5) (36.8) (41.2) 9 8 2 (10.5) (47.4) (52.9) 
   Multi-race 112 8 7 (5.5) (88.2) (93.3) 89 20 18 (14.2) (70.1) (81.7) 101 15 11 (8.7) (79.5) (87.1) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Declined 29 7 2 (5.3) (76.3) (80.6) 23 13 2 (5.3) (60.5) (63.9) 28 9 1 (2.6) (73.7) (75.7) 
   Don’t know/Not asked 110 70 34 (15.9) (51.4) (61.1) 70 85 59 (27.6) (32.7) (45.2) 115 61 38 (17.8) (53.7) (65.3) 
   Missing/Invalid 54 1 5 (8.3) (90.0) (98.2) 48 3 9 (15.0) (80.0) (94.1) 51 2 7 (11.7) (85.0) (96.2) 
Region                   
   Northeast 1,115 330 52 (3.5) (74.5) (77.2) 889 416 192 (12.8) (59.4) (68.1) 1,148 267 82 (5.5) (76.7) (81.1) 
   Midwest 658 44 260 (27.0) (68.4) (93.7) 475 90 397 (41.3) (49.4) (84.1) 566 66 330 (34.3) (58.8) (89.6) 
   South 3,761 548 1,631 (27.5) (63.3) (87.3) 2,832 735 2,373 (39.9) (47.7) (79.4) 3,140 796 2,004 (33.7) (52.9) (79.8) 
   West 1,178 241 42 (2.9) (80.6) (83.0) 861 539 61 (4.2) (58.9) (61.5) 1,004 357 100 (6.8) (68.7) (73.8) 
   U.S. dependent areas 259 19 6 (2.1) (91.2) (93.2) 249 25 10 (3.5) (87.7) (90.9) 245 30 9 (3.2) (86.3) (89.1) 
Target Populationb                    
   Male-to-male sexual contact and injection 
drug use 
143 13 13 (7.7) (84.6) (91.7) 104 35 30 (17.8) (61.5) (74.8) 119 29 21 (12.4) (70.4) (80.4) 
   Male-to-male sexual contact 3,415 280 267 (6.7) (86.2) (92.4) 2,691 631 640 (16.2) (67.9) (81.0) 3,002 569 391 (9.9) (75.8) (84.1) 
   Transgender and injection drug use 2 1 1 (25.0) (50.0) (66.7) 2 1 1 (25.0) (50.0) (66.7) 1 2 1 (25.0) (25.0) (33.3) 
   Transgender  71 11 6 (6.8) (80.7) (86.6) 52 14 22 (25.0) (59.1) (78.8) 52 16 20 (22.7) (59.1) (76.5) 
   Injection drug use 96 14 33 (23.1) (67.1) (87.3) 70 26 47 (32.9) (49.0) (72.9) 77 27 39 (27.3) (53.8) (74.0) 
   Heterosexual males 1,104 158 216 (14.6) (74.7) (87.5) 850 243 385 (26.0) (57.5) (77.8) 948 225 305 (20.6) (64.1) (80.8) 
   Heterosexual females 1,035 149 181 (13.3) (75.8) (87.4) 786 216 363 (26.6) (57.6) (78.4) 873 212 280 (20.5) (64.0) (80.5) 
   Not asked/No risk/Missing/Invalid 1,105 556 1,274 (43.4) (37.6) (66.5) 751 639 1,545 (52.6) (25.6) (54.0) 1,031 436 1,468 (50.0) (35.1) (70.3) 
Rapid test used in testing event                   
   Yes 4,447 733 753 (12.7) (75.0) (85.8) 3,555 1,191 1,187 (20.0) (59.9) (74.9) 3,758 1,003 1,172 (19.8) (63.3) (78.9) 
   No 2,519 449 1,237 (29.4) (59.9) (84.9) 1,751 614 1,840 (43.8) (41.6) (74.0) 2,345 513 1,347 (32.0) (55.8) (82.1) 
   Missing/Invalid 5 0 1 (16.7) (83.3) (100.0) 0 0 6 (100.0) (0.0) .... 0 0 6 (100.0) (0.0) .... 
Total 6,971 1,182 1,991 (19.6) (68.7) (85.5) 5,306 1,805 3,033 (29.9) (52.3) (74.6) 6,103 1,516 2,525 (24.9) (60.2) (80.1) 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data 
b Data to identify target populations are not required for persons who test HIV-negative in health care facilities. 
. 
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Table 10: HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics 
of newly identified HIV-positive persons tested in non-health care facilities from 61 health department jurisdictions 
providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                
   <13 2,040 10 (0.5) 3 5 2 (20.0) (30.0) (37.5) 2 1 7 (70.0) (20.0) (66.7) 
   13-19 80,712 229 (0.3) 120 38 71 (31.0) (52.4) (75.9) 104 14 111 (48.5) (45.4) (88.1) 
   20-29 397,430 2,819 (0.7) 1,638 431 750 (26.6) (58.1) (79.2) 1,351 164 1,304 (46.3) (47.9) (89.2) 
   30-39 224,851 1,636 (0.7) 988 227 421 (25.7) (60.4) (81.3) 805 80 751 (45.9) (49.2) (91.0) 
   40-49 143,267 1,285 (0.9) 725 224 336 (26.1) (56.4) (76.4) 608 98 579 (45.1) (47.3) (86.1) 
   50+ 126,419 1,032 (0.8) 549 224 259 (25.1) (53.2) (71.0) 452 122 458 (44.4) (43.8) (78.7) 
   Missing/Invalid 2,926 18 (0.6) 3 8 7 (38.9) (16.7) (27.3) 1 4 13 (72.2) (5.6) (20.0) 
Gender                
   Male 564,842 5,801 (1.0) 3,377 948 1,476 (25.4) (58.2) (78.1) 2,776 379 2,646 (45.6) (47.9) (88.0) 
   Female 403,638 1,098 (0.3) 588 182 328 (29.9) (53.6) (76.4) 492 95 511 (46.5) (44.8) (83.8) 
   Transgender 6,024 117 (1.9) 56 26 35 (29.9) (47.9) (68.3) 50 9 58 (49.6) (42.7) (84.7) 
   Declined/Not asked 1,587 7 (0.4) 4 1 2 (28.6) (57.1) (80.0) 4 0 3 (42.9) (57.1) (100.0) 
   Missing/Invalid 1,554 6 (0.4) 1 0 5 (83.3) (16.7) (100.0) 1 0 5 (83.3) (16.7) (100.0) 
Race/Ethnicity                
   White 259,958 1,401 (0.5) 899 180 322 (23.0) (64.2) (83.3) 750 71 580 (41.4) (53.5) (91.4) 
   Black or African American 414,038 3,766 (0.9) 1,951 740 1,075 (28.5) (51.8) (72.5) 1,610 338 1,818 (48.3) (42.8) (82.6) 
   Hispanic or Latino 229,917 1,476 (0.6) 974 174 328 (22.2) (66.0) (84.8) 783 51 642 (43.5) (53.0) (93.9) 
   Asian 22,392 119 (0.5) 69 16 34 (28.6) (58.0) (81.2) 59 9 51 (42.9) (49.6) (86.8) 
   American Indian or Alaska Native 8,743 33 (0.4) 12 6 15 (45.5) (36.4) (66.7) 12 2 19 (57.6) (36.4) (85.7) 
   Native Hawaiian or Pacific Islander 3,735 19 (0.5) 10 4 5 (26.3) (52.6) (71.4) 8 0 11 (57.9) (42.1) (100.0) 
   Multi-race 10,502 101 (1.0) 63 17 21 (20.8) (62.4) (78.8) 57 3 41 (40.6) (56.4) (95.0) 
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Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 daysa 
All testing events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Declined 3,414 19 (0.6) 9 3 7 (36.8) (47.4) (75.0) 9 1 9 (47.4) (47.4) (90.0) 
   Don’t know/Not asked 15,668 73 (0.5) 36 15 22 (30.1) (49.3) (70.6) 32 7 34 (46.6) (43.8) (82.1) 
   Missing/Invalid 9,278 22 (0.2) 3 2 17 (77.3) (13.6) (60.0) 3 1 18 (81.8) (13.6) (75.0) 
Region                
   Northeast 176,376 1,048 (0.6) 568 153 327 (31.2) (54.2) (78.8) 518 65 465 (44.4) (49.4) (88.9) 
   Midwest 84,289 675 (0.8) 340 108 227 (33.6) (50.4) (75.9) 306 74 295 (43.7) (45.3) (80.5) 
   South 555,514 4,160 (0.7) 2,374 709 1,077 (25.9) (57.1) (77.0) 1,841 277 2,042 (49.1) (44.3) (86.9) 
   West 150,977 1,097 (0.7) 717 173 207 (18.9) (65.4) (80.6) 632 65 400 (36.5) (57.6) (90.7) 
   U.S. dependent areas 10,489 49 (0.5) 27 14 8 (16.3) (55.1) (65.9) 26 2 21 (42.9) (53.1) (92.9) 
Target Populationb                
   Male-to-male sexual contact and injection drug use 4,292 150 (3.5) 96 22 32 (21.3) (64.0) (81.4) 78 9 63 (42.0) (52.0) (89.7) 
   Male-to-male sexual contact 148,982 3,531 (2.4) 2,208 570 753 (21.3) (62.5) (79.5) 2,027 199 1,305 (37.0) (57.4) (91.1) 
   Transgender and injection drug use 350 5 (1.4) 3 0 2 (40.0) (60.0) (100.0) 3 0 2 (40.0) (60.0) (100.0) 
   Transgender 5,674 112 (2.0) 53 26 33 (29.5) (47.3) (67.1) 47 9 56 (50.0) (42.0) (83.9) 
   Injection drug use 39,239 202 (0.5) 106 40 56 (27.7) (52.5) (72.6) 93 17 92 (45.5) (46.0) (84.5) 
   Heterosexual males 225,500 980 (0.4) 456 203 321 (32.8) (46.5) (69.2) 408 118 454 (46.3) (41.6) (77.6) 
   Heterosexual females 259,963 753 (0.3) 410 130 213 (28.3) (54.4) (75.9) 384 69 300 (39.8) (51.0) (84.8) 
   Not asked/No risk/Missing/Invalid 293,645 1,296 (0.4) 694 166 436 (33.6) (53.5) (80.7) 283 62 951 (73.4) (21.8) (82.0) 
Rapid test used in testing event                
   Yes 698,047 5,494 (0.8) 3,294 902 1,298 (23.6) (60.0) (78.5) 2,841 333 2,320 (42.2) (51.7) (89.5) 
   No 279,567 1,535 (0.5) 732 255 548 (35.7) (47.7) (74.2) 482 150 903 (58.8) (31.4) (76.3) 
   Missing/Invalid 31 0 (0.0) 0 0 0 .... .... .... 0 0 0 .... .... .... 
Total 977,645 7,029 (0.7) 4,026 1,157 1,846 (26.3) (57.3) (77.7) 3,323 483 3,223 (45.9) (47.3) (87.3) 
a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2013, data for 0.01% of newly identified HIV-positive individuals  
identified in non-health care facilities in 2013 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data. 
 b Data to identify target populations are not required for persons who test HIV-negative in health care facilities. 
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Table 11: HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of 
newly identified HIV-positive persons tested in non-health care facilities from 61 health department jurisdictions providing 
test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                   
   <13 6 3 1 (10.0) (60.0) (66.7) 4 5 1 (10.0) (40.0) (44.4) 8 1 1 (10.0) (80.0) (88.9) 
   13-19 167 23 39 (17.0) (72.9) (87.9) 104 34 91 (39.7) (45.4) (75.4) 109 37 83 (36.2) (47.6) (74.7) 
   20-29 2,048 329 442 (15.7) (72.6) (86.2) 1,349 504 966 (34.3) (47.9) (72.8) 1,552 446 821 (29.1) (55.1) (77.7) 
   30-39 1,207 163 266 (16.3) (73.8) (88.1) 873 265 498 (30.4) (53.4) (76.7) 873 246 517 (31.6) (53.4) (78.0) 
   40-49 896 189 200 (15.6) (69.7) (82.6) 653 259 373 (29.0) (50.8) (71.6) 634 221 430 (33.5) (49.3) (74.2) 
   50+ 690 201 141 (13.7) (66.9) (77.4) 501 249 282 (27.3) (48.5) (66.8) 498 171 363 (35.2) (48.3) (74.4) 
   Missing/Invalid 10 6 2 (11.1) (55.6) (62.5) 4 8 6 (33.3) (22.2) (33.3) 8 6 4 (22.2) (44.4) (57.1) 
Gender                   
   Male 4,143 754 904 (15.6) (71.4) (84.6) 2,858 1,101 1,842 (31.8) (49.3) (72.2) 3,074 911 1,816 (31.3) (53.0) (77.1) 
   Female 794 138 166 (15.1) (72.3) (85.2) 575 193 330 (30.1) (52.4) (74.9) 545 188 365 (33.2) (49.6) (74.4) 
   Transgender 75 21 21 (17.9) (64.1) (78.1) 49 28 40 (34.2) (41.9) (63.6) 58 26 33 (28.2) (49.6) (69.0) 
   Declined/Not asked 6 1 0 (0.0) (85.7) (85.7) 5 2 0 (0.0) (71.4) (71.4) 5 2 0 (0.0) (71.4) (71.4) 
   Missing/Invalid 6 0 0 (0.0) (100.0) (100.0) 1 0 5 (83.3) (16.7) (100.0) 0 1 5 (83.3) (0.0) (0.0) 
Race/Ethnicity                   
   White 1,078 129 194 (13.8) (76.9) (89.3) 775 226 400 (28.6) (55.3) (77.4) 786 227 388 (27.7) (56.1) (77.6) 
   Black or African American 2,597 600 569 (15.1) (69.0) (81.2) 1,684 792 1,290 (34.3) (44.7) (68.0) 1,878 591 1,297 (34.4) (49.9) (76.1) 
   Hispanic or Latino 1,054 140 282 (19.1) (71.4) (88.3) 841 230 405 (27.4) (57.0) (78.5) 810 254 412 (27.9) (54.9) (76.1) 
   Asian 94 11 14 (11.8) (79.0) (89.5) 63 26 30 (25.2) (52.9) (70.8) 71 13 35 (29.4) (59.7) (84.5) 
   American Indian or Alaska Native 26 2 5 (15.2) (78.8) (92.9) 14 3 16 (48.5) (42.4) (82.4) 12 2 19 (57.6) (36.4) (85.7) 
   Native Hawaiian or Pacific Islander 16 3 0 (0.0) (84.2) (84.2) 12 5 2 (10.5) (63.2) (70.6) 11 2 6 (31.6) (57.9) (84.6) 
   Multi-race 78 11 12 (11.9) (77.2) (87.6) 51 17 33 (32.7) (50.5) (75.0) 64 23 14 (13.9) (63.4) (73.6) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesa Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   Declined 13 6 0 (0.0) (68.4) (68.4) 12 6 1 (5.3) (63.2) (66.7) 7 4 8 (42.1) (36.8) (63.6) 
   Don’t know/Not asked 47 12 14 (19.2) (64.4) (79.7) 32 19 22 (30.1) (43.8) (62.7) 38 12 23 (31.5) (52.1) (76.0) 
   Missing/Invalid 21 0 1 (4.5) (95.5) (100.0) 4 0 18 (81.8) (18.2) (100.0) 5 0 17 (77.3) (22.7) (100.0) 
Region                   
   Northeast 704 113 231 (22.0) (67.2) (86.2) 474 167 407 (38.8) (45.2) (73.9) 751 108 189 (18.0) (71.7) (87.4) 
   Midwest 497 56 122 (18.1) (73.6) (89.9) 303 131 241 (35.7) (44.9) (69.8) 377 151 147 (21.8) (55.9) (71.4) 
   South 2,847 597 716 (17.2) (68.4) (82.7) 1,940 710 1,510 (36.3) (46.6) (73.2) 1,877 710 1,573 (37.8) (45.1) (72.6) 
   West 939 136 22 (2.0) (85.6) (87.3) 756 303 38 (3.5) (68.9) (71.4) 644 143 310 (28.3) (58.7) (81.8) 
   U.S. dependent areas 37 12 0 (0.0) (75.5) (75.5) 15 13 21 (42.9) (30.6) (53.6) 33 16 0 (0.0) (67.3) (67.3) 
Target Populationb                    
   Male-to-male sexual contact and 
injection drug use 
113 17 20 (13.3) (75.3) (86.9) 85 31 34 (22.7) (56.7) (73.3) 87 18 45 (30.0) (58.0) (82.9) 
   Male-to-male sexual contact 2,848 470 213 (6.0) (80.7) (85.8) 2,011 718 802 (22.7) (57.0) (73.7) 2,236 640 655 (18.5) (63.3) (77.7) 
   Transgender and injection drug use 4 0 1 (20.0) (80.0) (100.0) 4 0 1 (20.0) (80.0) (100.0) 2 1 2 (40.0) (40.0) (66.7) 
   Transgender 71 21 20 (17.9) (63.4) (77.2) 45 28 39 (34.8) (40.2) (61.6) 56 25 31 (27.7) (50.0) (69.1) 
   Injection drug use 151 22 29 (14.4) (74.8) (87.3) 105 40 57 (28.2) (52.0) (72.4) 121 25 56 (27.7) (59.9) (82.9) 
   Heterosexual males 727 178 75 (7.7) (74.2) (80.3) 491 212 277 (28.3) (50.1) (69.8) 467 173 340 (34.7) (47.7) (73.0) 
   Heterosexual females 609 97 47 (6.2) (80.9) (86.3) 443 135 175 (23.2) (58.8) (76.6) 408 148 197 (26.2) (54.2) (73.4) 
   Not asked/No risk/Missing/Invalid 501 109 686 (52.9) (38.7) (82.1) 304 160 832 (64.2) (23.5) (65.5) 305 98 893 (68.9) (23.5) (75.7) 
Rapid test used in testing event                   
   Yes 4,032 669 793 (14.4) (73.4) (85.8) 2,905 1,041 1,548 (28.2) (52.9) (73.6) 3,162 956 1,376 (25.0) (57.6) (76.8) 
   No 992 245 298 (19.4) (64.6) (80.2) 583 283 669 (43.6) (38.0) (67.3) 520 172 843 (54.9) (33.9) (75.1) 
Total 5,024 914 1,091 (15.5) (71.5) (84.6) 3,488 1,324 2,217 (31.5) (49.6) (72.5) 3,682 1,128 2,219 (31.6) (52.4) (76.5) 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data 
   b Data to identify target populations are not required for persons who test HIV-negative in health care facilities. 
. 
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Table 12a: HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics 
of newly identified HIV-positive men who have sex with men (MSM) in non-health care facilities from 61 health 
department jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) 
Age at test (years)                
   <13 136 1 (0.7) 0 1 0 (0.0) (0.0) (0.0) 0 0 1 (100.0) (0.0) .... 
   13-19 7,279 133 (1.8) 75 30 28 (21.1) (56.4) (71.4) 67 12 54 (40.6) (50.4) (84.8) 
   20-29 67,454 1,917 (2.8) 1,190 311 416 (21.7) (62.1) (79.3) 1,084 122 711 (37.1) (56.5) (89.9) 
   30-39 36,085 852 (2.4) 544 128 180 (21.1) (63.8) (81.0) 501 35 316 (37.1) (58.8) (93.5) 
   40-49 23,205 487 (2.1) 315 73 99 (20.3) (64.7) (81.2) 293 17 177 (36.3) (60.2) (94.5) 
   50+ 18,647 287 (1.5) 179 49 59 (20.6) (62.4) (78.5) 159 22 106 (36.9) (55.4) (87.8) 
   Missing/Invalid 468 4 (0.9) 1 0 3 (75.0) (25.0) (100.0) 1 0 3 (75.0) (25.0) (100.0) 
Race/Ethnicity                
   White 66,404 957 (1.4) 645 119 193 (20.2) (67.4) (84.4) 582 46 329 (34.4) (60.8) (92.7) 
   Black or African American 34,169 1,613 (4.7) 913 323 377 (23.4) (56.6) (73.9) 832 125 656 (40.7) (51.6) (86.9) 
   Hispanic or Latino 38,650 874 (2.3) 604 109 161 (18.4) (69.1) (84.7) 560 24 290 (33.2) (64.1) (95.9) 
   Asian 7,093 88 (1.2) 58 13 17 (19.3) (65.9) (81.7) 51 8 29 (33.0) (58.0) (86.4) 
   American Indian or Alaska Native 949 14 (1.5) 5 4 5 (35.7) (35.7) (55.6) 5 1 8 (57.1) (35.7) (83.3) 
   Native Hawaiian or Pacific Islander 763 13 (1.7) 8 3 2 (15.4) (61.5) (72.7) 7 0 6 (46.2) (53.8) (100.0) 
   Multi-race 2,886 75 (2.6) 45 16 14 (18.7) (60.0) (73.8) 43 3 29 (38.7) (57.3) (93.5) 
   Declined 885 14 (1.6) 8 3 3 (21.4) (57.1) (72.7) 8 1 5 (35.7) (57.1) (88.9) 
   Don’t know/Not asked 1,282 26 (2.0) 15 2 9 (34.6) (57.7) (88.2) 14 0 12 (46.2) (53.8) (100.0) 
   Missing/Invalid 193 7 (3.6) 3 0 4 (57.1) (42.9) (100.0) 3 0 4 (57.1) (42.9) (100.0) 
Region                
   Northeast 20,108 509 (2.5) 310 64 135 (26.5) (60.9) (82.9) 287 24 198 (38.9) (56.4) (92.3) 
   Midwest 21,173 429 (2.0) 258 79 92 (21.4) (60.1) (76.6) 235 54 140 (32.6) (54.8) (81.3) 
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Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) 
   South 60,565 1,927 (3.2) 1,204 306 417 (21.6) (62.5) (79.7) 1,116 84 727 (37.7) (57.9) (93.0) 
   West 49,782 785 (1.6) 519 131 135 (17.2) (66.1) (79.8) 455 45 285 (36.3) (58.0) (91.0) 
   U.S. dependent areas 1,646 31 (1.9) 13 12 6 (19.4) (41.9) (52.0) 12 1 18 (58.1) (38.7) (92.3) 
Rapid test used in testing event                
   Yes 141,852 3,224 (2.3) 2,053 523 648 (20.1) (63.7) (79.7) 1,894 167 1,163 (36.1) (58.7) (91.9) 
   No 11,420 457 (4.0) 251 69 137 (30.0) (54.9) (78.4) 211 41 205 (44.9) (46.2) (83.7) 
   Missing/Invalid 2 0 (0.0) 0 0 0 .... .... .... 0 0 0 .... .... .... 
Total 153,274 3,681 (2.4) 2,304 592 785 (21.3) (62.6) (79.6) 2,105 208 1,368 (37.2) (57.2) (91.0) 
aBehavioral data used to classify persons as MSM and all other target population categories are only required to be collected for test events conducted in non-health care facilities and for all HIV-positive persons in health care facilities. Because 
of this denominators are unknown for negatives tested in  health care facilities; therefore only non-health care testing events are accounted for here. 
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Table 13a: HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of 
newly identified HIV-positive men who have sex with men (MSM) in non-health care facilities from 61 health department 
jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
Referred to Partner Services Interviewed for Partner Servicesb Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                   
   <13 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
   13-19 109 15 9 (6.8) (82.0) (87.9) 67 23 43 (32.3) (50.4) (74.4) 78 21 34 (25.6) (58.6) (78.8) 
   20-29 1,539 252 126 (6.6) (80.3) (85.9) 1,036 390 491 (25.6) (54.0) (72.7) 1,238 331 348 (18.2) (64.6) (78.9) 
   30-39 695 107 50 (5.9) (81.6) (86.7) 526 173 153 (18.0) (61.7) (75.3) 529 147 176 (20.7) (62.1) (78.3) 
   40-49 392 63 32 (6.6) (80.5) (86.2) 303 97 87 (17.9) (62.2) (75.8) 301 104 82 (16.8) (61.8) (74.3) 
   50+ 222 49 16 (5.6) (77.4) (81.9) 161 65 61 (21.3) (56.1) (71.2) 174 53 60 (20.9) (60.6) (76.7) 
   Missing/Invalid 3 1 0 (0.0) (75.0) (75.0) 2 1 1 (25.0) (50.0) (66.7) 2 2 0 (0.0) (50.0) (50.0) 
Race/Ethnicity                   
   White 808 86 63 (6.6) (84.4) (90.4) 594 157 206 (21.5) (62.1) (79.1) 604 170 183 (19.1) (63.1) (78.0) 
   Black or African American 1,240 273 100 (6.2) (76.9) (82.0) 771 376 466 (28.9) (47.8) (67.2) 1,007 266 340 (21.1) (62.4) (79.1) 
   Hispanic or Latino 725 100 49 (5.6) (83.0) (87.9) 599 168 107 (12.2) (68.5) (78.1) 565 179 130 (14.9) (64.6) (75.9) 
   Asian 72 8 8 (9.1) (81.8) (90.0) 55 19 14 (15.9) (62.5) (74.3) 59 12 17 (19.3) (67.0) (83.1) 
   American Indian or Alaska Native 11 1 2 (14.3) (78.6) (91.7) 6 1 7 (50.0) (42.9) (85.7) 8 0 6 (42.9) (57.1) (100.0) 
   Native Hawaiian or Pacific Islander 10 3 0 (0.0) (76.9) (76.9) 8 5 0 (0.0) (61.5) (61.5) 8 2 3 (23.1) (61.5) (80.0) 
   Multi-race 57 8 10 (13.3) (76.0) (87.7) 36 14 25 (33.3) (48.0) (72.0) 46 20 9 (12.0) (61.3) (69.7) 
   Declined 11 3 0 (0.0) (78.6) (78.6) 10 3 1 (7.1) (71.4) (76.9) 6 4 4 (28.6) (42.9) (60.0) 
   Don’t know/Not asked 20 5 1 (3.8) (76.9) (80.0) 14 6 6 (23.1) (53.8) (70.0) 17 5 4 (15.4) (65.4) (77.3) 
   Missing/Invalid 7 0 0 (0.0) (100.0) (100.0) 3 0 4 (57.1) (42.9) (100.0) 3 0 4 (57.1) (42.9) (100.0) 
Region                   
   Northeast 367 69 73 (14.3) (72.1) (84.2) 215 104 190 (37.3) (42.2) (67.4) 403 38 68 (13.4) (79.2) (91.4) 
   Midwest 341 44 44 (10.3) (79.5) (88.6) 212 93 124 (28.9) (49.4) (69.5) 268 115 46 (10.7) (62.5) (70.0) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesb Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   South 1,557 268 102 (5.3) (80.8) (85.3) 1,113 324 490 (25.4) (57.8) (77.5) 1,162 381 384 (19.9) (60.3) (75.3) 
   West 677 94 14 (1.8) (86.2) (87.8) 546 216 23 (2.9) (69.6) (71.7) 474 109 202 (25.7) (60.4) (81.3) 
   U.S. dependent areas 19 12 0 (0.0) (61.3) (61.3) 10 12 9 (29.0) (32.3) (45.5) 16 15 0 (0.0) (51.6) (51.6) 
Rapid test used in testing event                   
   Yes 2,577 427 220 (6.8) (79.9) (85.8) 1,841 668 715 (22.2) (57.1) (73.4) 2,080 587 557 (17.3) (64.5) (78.0) 
   No 384 60 13 (2.8) (84.0) (86.5) 255 81 121 (26.5) (55.8) (75.9) 243 71 143 (31.3) (53.2) (77.4) 
Total 2,961 487 233 (6.3) (80.4) (85.9) 2,096 749 836 (22.7) (56.9) (73.7) 2,323 658 700 (19.0) (63.1) (77.9) 
aBehavioral data used to classify persons as MSM and all other target population categories are only required to be collected for test events conducted in non-health care facilities and for all HIV-positive persons in health care facilities. Because 
of this denominators are unknown for negatives tested in  health care facilities; therefore only non-health care testing events are accounted for here. 
b Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 14a: HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics of 
newly identified HIV-positive heterosexual females in non-health care facilities from 61 health department jurisdictions 
providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) 
Age at test (years)                
   <13 151 0 (0.0) 0 0 0 .... .... .... 0 0 0 .... .... .... 
   13-19 27,584 30 (0.1) 19 2 9 (30.0) (63.3) (90.5) 18 0 12 (40.0) (60.0) (100.0) 
   20-29 116,126 167 (0.1) 90 21 56 (33.5) (53.9) (81.1) 86 12 69 (41.3) (51.5) (87.8) 
   30-39 58,951 182 (0.3) 113 18 51 (28.0) (62.1) (86.3) 107 9 66 (36.3) (58.8) (92.2) 
   40-49 33,196 206 (0.6) 101 53 52 (25.2) (49.0) (65.6) 95 24 87 (42.2) (46.1) (79.8) 
   50+ 23,153 163 (0.7) 86 35 42 (25.8) (52.8) (71.1) 78 22 63 (38.7) (47.9) (78.0) 
   Missing/Invalid 802 5 (0.6) 1 1 3 (60.0) (20.0) (50.0) 0 2 3 (60.0) (0.0) (0.0) 
Race/Ethnicity                
   White 58,103 80 (0.1) 46 10 24 (30.0) (57.5) (82.1) 42 4 34 (42.5) (52.5) (91.3) 
   Black or African American 134,725 542 (0.4) 289 102 151 (27.9) (53.3) (73.9) 273 57 212 (39.1) (50.4) (82.7) 
   Hispanic or Latino 53,098 105 (0.2) 62 14 29 (27.6) (59.0) (81.6) 57 6 42 (40.0) (54.3) (90.5) 
   Asian 3,763 5 (0.1) 5 0 0 (0.0) (100.0) (100.0) 4 0 1 (20.0) (80.0) (100.0) 
   American Indian or Alaska Native 2,544 5 (0.2) 2 0 3 (60.0) (40.0) (100.0) 2 0 3 (60.0) (40.0) (100.0) 
   Native Hawaiian or Pacific Islander 572 1 (0.2) 0 0 1 (100.0) (0.0) .... 0 0 1 (100.0) (0.0) .... 
   Multi-race 2,816 7 (0.2) 4 1 2 (28.6) (57.1) (80.0) 4 0 3 (42.9) (57.1) (100.0) 
   Declined 710 2 (0.3) 1 0 1 (50.0) (50.0) (100.0) 1 0 1 (50.0) (50.0) (100.0) 
   Don’t know/Not asked 1,427 5 (0.4) 1 3 1 (20.0) (20.0) (25.0) 1 2 2 (40.0) (20.0) (33.3) 
   Missing/Invalid 2,205 1 (0.0) 0 0 1 (100.0) (0.0) .... 0 0 1 (100.0) (0.0) .... 
Region                
   Northeast 29,808 128 (0.4) 73 24 31 (24.2) (57.0) (75.3) 71 6 51 (39.8) (55.5) (92.2) 
   Midwest 19,048 45 (0.2) 25 6 14 (31.1) (55.6) (80.6) 22 5 18 (40.0) (48.9) (81.5) 
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Characteristics 
HIV testing events Linkage to HIV Medical Care Linkage to HIV Medical Care in 90 days 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) Linked 
Not 
linked 
Missing 
/Invalid 
(Missing 
/Invalid %) 
(Minimum 
Indicator %) 
(Maximum 
Indicator %) 
   South 181,457 507 (0.3) 262 89 156 (30.8) (51.7) (74.6) 246 53 208 (41.0) (48.5) (82.3) 
   West 25,901 71 (0.3) 48 11 12 (16.9) (67.6) (81.4) 43 5 23 (32.4) (60.6) (89.6) 
   U.S. dependent areas 3,749 2 (0.1) 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 
Rapid test used in testing event                
   Yes 155,771 525 (0.3) 310 89 126 (24.0) (59.0) (77.7) 293 45 187 (35.6) (55.8) (86.7) 
   No 104,191 228 (0.2) 100 41 87 (38.2) (43.9) (70.9) 91 24 113 (49.6) (39.9) (79.1) 
   Missing/Invalid 1 0 (0.0) 0 0 0 .... .... .... 0 0 0 .... .... .... 
Total 259,963 753 (0.3) 410 130 213 (28.3) (54.4) (75.9) 384 69 300 (39.8) (51.0) (84.8) 
aBehavioral data used to classify persons as MSM and all other target population categories are only required to be collected for test events conducted in non-health care facilities and for all HIV-positive persons in health care facilities. Because 
of this denominators are unknown for negatives tested in health care facilities; therefore only non-health care testing events are accounted for here. 
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Table 15a: HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of 
newly identified HIV-positive heterosexual females in non-health care facilities from 61 health department jurisdictions 
providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2013 
Characteristics 
Referred to Partner Services Interviewed for Partner Servicesb Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
Age at test (years)                   
   <13 0 0 0 ---- ---- ---- 0 0 0 ---- ---- ---- 0 0 0 ---- ---- ---- 
   13-19 25 4 1 (3.3) (83.3) (86.2) 17 4 9 (30.0) (56.7) (81.0) 11 9 10 (33.3) (36.7) (55.0) 
   20-29 141 12 14 (8.4) (84.4) (92.2) 101 17 49 (29.3) (60.5) (85.6) 93 26 48 (28.7) (55.7) (78.2) 
   30-39 155 14 13 (7.1) (85.2) (91.7) 117 23 42 (23.1) (64.3) (83.6) 108 35 39 (21.4) (59.3) (75.5) 
   40-49 158 35 13 (6.3) (76.7) (81.9) 113 50 43 (20.9) (54.9) (69.3) 101 42 63 (30.6) (49.0) (70.6) 
   50+ 126 31 6 (3.7) (77.3) (80.3) 93 40 30 (18.4) (57.1) (69.9) 93 35 35 (21.5) (57.1) (72.7) 
   Missing/Invalid 4 1 0 (0.0) (80.0) (80.0) 2 1 2 (40.0) (40.0) (66.7) 2 1 2 (40.0) (40.0) (66.7) 
Race/Ethnicity                   
   White 70 8 2 (2.5) (87.5) (89.7) 46 10 24 (30.0) (57.5) (82.1) 49 12 19 (23.8) (61.3) (80.3) 
   Black or African American 439 74 29 (5.4) (81.0) (85.6) 320 103 119 (22.0) (59.0) (75.7) 283 109 150 (27.7) (52.2) (72.2) 
   Hispanic or Latino 81 11 13 (12.4) (77.1) (88.0) 66 17 22 (21.0) (62.9) (79.5) 64 27 14 (13.3) (61.0) (70.3) 
   Asian 5 0 0 (0.0) (100.0) (100.0) 4 1 0 (0.0) (80.0) (80.0) 5 0 0 (0.0) (100.0) (100.0) 
   American Indian or Alaska Native 5 0 0 (0.0) (100.0) (100.0) 2 0 3 (60.0) (40.0) (100.0) 1 0 4 (80.0) (20.0) (100.0) 
   Native Hawaiian or Pacific Islander 1 0 0 (0.0) (100.0) (100.0) 0 0 1 (100.0) (0.0) .... 0 0 1 (100.0) (0.0) .... 
   Multi-race 5 1 1 (14.3) (71.4) (83.3) 3 1 3 (42.9) (42.9) (75.0) 4 0 3 (42.9) (57.1) (100.0) 
   Declined 1 1 0 (0.0) (50.0) (50.0) 1 1 0 (0.0) (50.0) (50.0) 1 0 1 (50.0) (50.0) (100.0) 
   Don’t know/Not asked 1 2 2 (40.0) (20.0) (33.3) 1 2 2 (40.0) (20.0) (33.3) 1 0 4 (80.0) (20.0) (100.0) 
   Missing/Invalid 1 0 0 (0.0) (100.0) (100.0) 0 0 1 (100.0) (0.0) .... 0 0 1 (100.0) (0.0) .... 
Region                   
   Northeast 98 9 21 (16.4) (76.6) (91.6) 77 18 33 (25.8) (60.2) (81.1) 98 14 16 (12.5) (76.6) (87.5) 
   Midwest 37 2 6 (13.3) (82.2) (94.9) 24 4 17 (37.8) (53.3) (85.7) 29 7 9 (20.0) (64.4) (80.6) 
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Characteristics 
Referred to Partner Services Interviewed for Partner Servicesb Referred to HIV Prevention Services 
Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Interviewed 
Not 
Interviewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) Referred 
Not 
Referred 
Missing 
/invalid 
(Missing 
%) 
(Minimum 
Indicator 
%) 
(Maximum 
Indicator 
%) 
   South 413 75 19 (3.7) (81.5) (84.6) 295 89 123 (24.3) (58.2) (76.8) 233 116 158 (31.2) (46.0) (66.8) 
   West 59 11 1 (1.4) (83.1) (84.3) 45 24 2 (2.8) (63.4) (65.2) 46 11 14 (19.7) (64.8) (80.7) 
   U.S. dependent areas 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 
Rapid test used in testing event                   
   Yes 428 58 39 (7.4) (81.5) (88.1) 331 89 105 (20.0) (63.0) (78.8) 316 114 95 (18.1) (60.2) (73.5) 
   No 181 39 8 (3.5) (79.4) (82.3) 112 46 70 (30.7) (49.1) (70.9) 92 34 102 (44.7) (40.4) (73.0) 
Total 609 97 47 (6.2) (80.9) (86.3) 443 135 175 (23.2) (58.8) (76.6) 408 148 197 (26.2) (54.2) (73.4) 
aBehavioral data used to classify persons as MSM and all other target population categories are only required to be collected for test events conducted in non-health care facilities and for all HIV-positive persons in health care facilities. Because 
of this denominators are unknown for negatives tested in  health care facilities; therefore only non-health care testing events are accounted for here. 
b Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 16:  HIV testing and linkage to HIV medical care indicators in the United States, Puerto Rico, and the U.S. Virgin Islands, 
2011-2013. 
  
Characteristics 
2011 2012 2013 
HIV 
testing 
events 
Newly identified 
HIV-positive 
testing events 
Linkage to HIV medical 
care 
HIV 
testing 
events 
Newly identified 
HIV-positive 
testing events 
Linkage to HIV medical 
care 
HIV testing 
events 
Newly identified 
HIV-positive 
testing events 
Linkage to HIV medical 
care 
No. No. (%) Linked Linkage % 
(Min-Max) 
No. No. (%) Linked Linkage % 
(Min-Max) 
No. No. (%) Linked Linkage % 
(Min-Max) 
Age at test (years) 
                              
<13          6,842           32        0.5           13   (40.6-72.2)           5,133           18        0.4             6   (33.3-54.5)           5,537           25  0.5            8   (32.0-44.4)  
13-19      336,134         617        0.2         206   (33.4-64.4)       303,523         606        0.2         288   (47.5-66.7)       279,412         579  0.2        309   (53.4-74.6)  
20-29   1,353,872      6,539        0.5      2,651   (40.5-70.2)    1,346,543      6,710        0.5      3,406   (50.8-67.5)    1,358,687      6,895  0.5     4,080   (59.2-78.0)  
30-39      701,634      4,062        0.6      1,698   (41.8-72.7)       725,598      4,083        0.6      2,186   (53.5-68.9)       756,782      4,118  0.5     2,493   (60.5-78.7)  
40-49      473,233      3,443        0.7      1,405   (40.8-70.5)       463,353      3,212        0.7      1,640   (51.1-66.8)       461,696      3,056  0.7     1,779   (58.2-76.5)  
50+      400,901      2,328        0.6         904   (38.8-68.4)       423,382      2,296        0.5      1,152   (50.2-63.9)       456,169      2,434  0.5     1,416   (58.2-75.7)  
Gender                               
Male   1,593,617    13,372        0.8      5,535   (41.4-70.6)    1,574,184    13,333        0.8      6,954   (52.2-67.5)    1,632,645    13,976  0.9     8,412   (60.2-77.8)  
Female   1,686,164      3,587        0.2      1,357   (37.8-71.1)    1,679,449      3,304        0.2      1,591   (48.2-65.9)    1,687,367      3,188  0.2     1,740   (54.6-76.4)  
Other specified  ─   ─   ─   ─   ─           8,740           61        0.7           31   (50.8-58.5)  0 0 ─ 0 ─ 
Race/Ethnicity                               
White      892,419      3,735        0.4      1,575   (42.2-72.0)       895,814      3,523        0.4      1,851   (52.5-67.1)       901,973      3,445  0.4     2,160   (62.7-80.1)  
Black or African/American   1,470,077      9,217        0.6      3,340   (36.2-66.9)    1,444,796      8,884        0.6      4,138   (46.6-63.8)    1,506,016      9,571  0.6     5,121   (53.5-73.8)  
Hispanic or Latino      683,241      3,427        0.5      1,761   (51.4-78.2)       686,757      3,497        0.5      2,219   (63.5-76.6)       713,058      3,407  0.5     2,424   (71.1-84.9)  
Asian        54,411         202        0.4         105   (52.0-82.7)         62,832         236        0.4         133   (56.4-68.9)         66,997         243  0.4        155   (63.8-80.3)  
American Indian or Alaska Native        16,500           55        0.3           16   (29.1-72.7)         16,566           87        0.5           33   (37.9-51.6)         16,587           55  0.3          25   (45.5-71.4)  
Native Hawaiian or Pacific Islander          8,443           42        0.5           21   (50.0-77.8)           8,148           41        0.5           24   (58.5-75.0)           8,466           38  0.4          23   (60.5-76.7)  
Multi-race        26,423         160        0.6           62   (38.8-70.5)         22,413         149        0.7           88   (59.1-69.8)         22,758         229  1.0        153   (66.8-80.1)  
Testing site type                               
Health care facilities including correctional 
facility clinics   2,424,918      9,910        0.4      4,036   (40.7-68.1)    2,297,501      9,994        0.4      5,154   (51.6-67.9)    2,298,949    10,144  0.4     6,229   (61.4-77.5)  
Non-health care facilities      702,880      6,678        1.0      2,831   (42.4-75.0)       985,611      6,976        0.7      3,547   (50.8-66.1)       977,645      7,029  0.7     4,026   (57.3-77.7)  
Other facilities      130,117         529        0.4           95   (18.0-60.1)                  2  0  ─  0  ─  0 0 ─ 0 ─ 
Total 
  3,299,690    17,222        0.5      6,992   (40.6-70.7)    3,287,024    16,976        0.5      8,702   (51.3-67.1)    3,343,633    17,426  0.5   10,286   (59.0-77.5)  
Note: Only jurisdictions with test-level data are included in this table: 55 jurisdictions were included in 2011, 59 in 2012, and all 61 in 2013. 
